<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6359475</article-id><article-id pub-id-type="doi">10.3390/ijms20020372</article-id><article-id pub-id-type="publisher-id">ijms-20-00372</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Tocotrienols Modulate a Life or Death Decision in Cancers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tham</surname><given-names>Shiau-Ying</given-names></name><xref ref-type="aff" rid="af1-ijms-20-00372">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6173-6367</contrib-id><name><surname>Loh</surname><given-names>Hwei-San</given-names></name><xref ref-type="aff" rid="af1-ijms-20-00372">1</xref><xref ref-type="aff" rid="af2-ijms-20-00372">2</xref><xref rid="c1-ijms-20-00372" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Mai</surname><given-names>Chun-Wai</given-names></name><xref ref-type="aff" rid="af3-ijms-20-00372">3</xref><xref ref-type="aff" rid="af4-ijms-20-00372">4</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Ju-Yen</given-names></name><xref ref-type="aff" rid="af5-ijms-20-00372">5</xref><xref rid="c1-ijms-20-00372" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-ijms-20-00372"><label>1</label>School of Biosciences, Faculty of Science and Engineering, University of Nottingham Malaysia Campus, Jalan Broga, Semenyih 43500, Malaysia; <email>ShiauYing.Tham@nottingham.edu.my</email></aff><aff id="af2-ijms-20-00372"><label>2</label>Biotechnology Research Centre, University of Nottingham Malaysia Campus, Jalan Broga, Semenyih 43500, Malaysia</aff><aff id="af3-ijms-20-00372"><label>3</label>School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia; <email>chunwai_mai@imu.edu.my</email></aff><aff id="af4-ijms-20-00372"><label>4</label>Centre for Cancer and Stem Cell Research, Institute for Research, Development and Innovation, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia</aff><aff id="af5-ijms-20-00372"><label>5</label>Nutrition Unit, Product Development and Advisory Services Division, Malaysian Palm Oil Board, 6 Persiaran Institusi, Bandar Baru Bangi, Kajang 43000, Malaysia</aff><author-notes><corresp id="c1-ijms-20-00372"><label>*</label>Correspondence: <email>Sandy.Loh@nottingham.edu.my</email> (H.-S.L.); <email>fujuyen@gmail.com</email> (J.-Y.F.); Tel.: +603-8924-8215 (H.-S.L.); +603-8769-4592 (J.-Y.F.)</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2019</year></pub-date><volume>20</volume><issue>2</issue><elocation-id>372</elocation-id><history><date date-type="received"><day>26</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Malignancy often arises from sophisticated defects in the intricate molecular mechanisms of cells, rendering a complicated molecular ground to effectively target cancers. Resistance toward cell death and enhancement of cell survival are the common adaptations in cancer due to its infinite proliferative capacity. Existing cancer treatment strategies that target a single molecular pathway or cancer hallmark fail to fully resolve the problem. Hence, multitargeted anticancer agents that can concurrently target cell death and survival pathways are seen as a promising alternative to treat cancer. Tocotrienols, a minor constituent of the vitamin E family that have previously been reported to induce various cell death mechanisms and target several key survival pathways, could be an effective anticancer agent. This review puts forward the potential application of tocotrienols as an anticancer treatment from a perspective of influencing the life or death decision of cancer cells. The cell death mechanisms elicited by tocotrienols, particularly apoptosis and autophagy, are highlighted. The influences of several cell survival signaling pathways in shaping cancer cell death, particularly NF-&#x003ba;B, PI3K/Akt, MAPK, and Wnt, are also reviewed. This review may stimulate further mechanistic researches and foster clinical applications of tocotrienols via rational drug designs.</p></abstract><kwd-group><kwd>tocotrienols</kwd><kwd>cancer</kwd><kwd>cell death</kwd><kwd>cell survival</kwd><kwd>autophagy</kwd><kwd>apoptosis</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-20-00372"><title>1. Introduction</title><p>Cancer incidence rate has been increasing steadily every year, imposing significant social and economic impacts globally. In 2018, it was estimated that new cancer cases and mortality would increase to 18.1 million and 9.6 million, respectively, for the world population. In other words, 1 in 5 men and 1 in 6 women may develop cancer in their lifetime, while 1 in 8 men and 1 in 11 women may die from cancer [<xref rid="B1-ijms-20-00372" ref-type="bibr">1</xref>]. In the United States (US) alone, it was predicted that there would be about 1.74 million new cancer cases, and approximately 600,000 people would eventually die from this disease in 2018. The estimated national expenditure for cancer care in the US was $147.3 billion in 2017. This figure is expected to increase continuously due to a high prevalence of cancer cases in aged population [<xref rid="B2-ijms-20-00372" ref-type="bibr">2</xref>].</p><p>Chemotherapy has been the pillar for cancer disease management. However, the effectiveness of these drugs is often limited by challenges such as tumor immune evasion [<xref rid="B3-ijms-20-00372" ref-type="bibr">3</xref>,<xref rid="B4-ijms-20-00372" ref-type="bibr">4</xref>], high-dose toxicities, and drug resistance development through tumor microenvironment [<xref rid="B4-ijms-20-00372" ref-type="bibr">4</xref>] or inappropriate cancer metabolism [<xref rid="B5-ijms-20-00372" ref-type="bibr">5</xref>], which eventually lead to cancer metastasis and recurrence. Hence, more effective and potent anticancer agents are needed to save more lives from cancer death. Guided by several previous successes of isolating chemotherapeutic agents from plant sources, such as etoposide, paclitaxel, and vinblastine, considerable attention has been given to identify more effective anticancer agents or novel chemical entities from plant reservoirs [<xref rid="B6-ijms-20-00372" ref-type="bibr">6</xref>,<xref rid="B7-ijms-20-00372" ref-type="bibr">7</xref>,<xref rid="B8-ijms-20-00372" ref-type="bibr">8</xref>,<xref rid="B9-ijms-20-00372" ref-type="bibr">9</xref>,<xref rid="B10-ijms-20-00372" ref-type="bibr">10</xref>,<xref rid="B11-ijms-20-00372" ref-type="bibr">11</xref>,<xref rid="B12-ijms-20-00372" ref-type="bibr">12</xref>]. Exhibiting cancer selectivity and exerting multitargeted actions for effectively killing various types of cancers, tocotrienols (T3) appear as a promising, novel anticancer candidate. The anticancer mechanisms of tocotrienols, including antiproliferation, promotion of apoptosis, and inhibitions of angiogenesis, cancer invasion, and metastasis, have been previously well reported and reviewed [<xref rid="B13-ijms-20-00372" ref-type="bibr">13</xref>,<xref rid="B14-ijms-20-00372" ref-type="bibr">14</xref>,<xref rid="B15-ijms-20-00372" ref-type="bibr">15</xref>]. In fact, these pleiotropic effects portray value-added actions of tocotrienols in targeting cancers.</p><p>Tocotrienols, which belong to the vitamin E family, are naturally occurring compounds that can be found in plant seeds, such as rice bran, oil palm, and annatto [<xref rid="B16-ijms-20-00372" ref-type="bibr">16</xref>]. They exist in four isomeric forms, namely, alpha (&#x003b1;)-, beta (&#x003b2;)-, gamma (&#x003b3;)-, and delta (&#x003b4;)-T3, which are distinguished by the position and number of methyl groups in the chromanal head. Depending on the source of tocotrienols, their composition of T3 isomers varies. For example, &#x003b3;-T3 is predominantly higher in rice and palm compared to annatto, which mainly consists of &#x003b4;-T3. Of note, &#x003b3;-T3 and &#x003b4;-T3 have been reported to exert most potent anticancer effects [<xref rid="B17-ijms-20-00372" ref-type="bibr">17</xref>,<xref rid="B18-ijms-20-00372" ref-type="bibr">18</xref>,<xref rid="B19-ijms-20-00372" ref-type="bibr">19</xref>,<xref rid="B20-ijms-20-00372" ref-type="bibr">20</xref>]. Other than pure isomers, tocotrienol-rich fraction (TRF) is the most commonly available form of vitamin E oral supplement, containing a mixture of &#x003b1;-, &#x003b3;-, &#x003b4;-T3, and some &#x003b1;-tocopherol. TRF has also been shown to exhibit apoptosis [<xref rid="B21-ijms-20-00372" ref-type="bibr">21</xref>] and induce cell cycle arrest [<xref rid="B22-ijms-20-00372" ref-type="bibr">22</xref>] and growth inhibition of human colon xenografts in nude mice [<xref rid="B23-ijms-20-00372" ref-type="bibr">23</xref>]. Hence, the anticancer effects of &#x003b3;-T3, &#x003b4;-T3, and TRF are emphasized in this review.</p><p>Therapeutic intervention targeting a single hallmark of cancer de facto is unlikely to cure the disease [<xref rid="B24-ijms-20-00372" ref-type="bibr">24</xref>]. This is because cancer arises from multiple mutations and lies within an aberrant and complex physiological network, rendering a unique identity for each tumor in different individuals [<xref rid="B25-ijms-20-00372" ref-type="bibr">25</xref>]. In the process of transforming healthy cells to cancer cells, the core changes include increased proliferation and decreased cell death [<xref rid="B26-ijms-20-00372" ref-type="bibr">26</xref>]. Therefore, it is important to reverse the state when applying an anticancer therapy. Particularly, targeting cell death and survival pathways may offer advantages for rapid and effective elimination of cancer cells and avoid drug resistance development and subsequent progression of cancers into advanced stages.</p><p>Several recent reviews have comprehensively summarized the general biological effects of tocotrienols, including anti-inflammation, antihyperlipidemic, immunomodulation, neuroprotection, gastroprotection, hepatoprotection, nephroprotection, radioprotection, and anticancer [<xref rid="B27-ijms-20-00372" ref-type="bibr">27</xref>,<xref rid="B28-ijms-20-00372" ref-type="bibr">28</xref>,<xref rid="B29-ijms-20-00372" ref-type="bibr">29</xref>]. Despite the enormous pharmacological and biological potentials of tocotrienols, as reviewed previously [<xref rid="B15-ijms-20-00372" ref-type="bibr">15</xref>,<xref rid="B27-ijms-20-00372" ref-type="bibr">27</xref>,<xref rid="B28-ijms-20-00372" ref-type="bibr">28</xref>,<xref rid="B29-ijms-20-00372" ref-type="bibr">29</xref>], the actions of tocotrienols in promoting cell death and blocking survival via various pathways have not been reviewed in an integrated manner. Hence, the present review comprehensively gathers the evidences of different cell death modalities induced by tocotrienols in order to provide a global view on the molecular mechanisms and an integrated understanding between cell death and survival signaling pathways for therapeutic benefits.</p></sec><sec id="sec2-ijms-20-00372"><title>2. Programmed Cell Death in Cancer</title><p>Programmed cell death (PCD) is an evolutionary conserved cellular mechanism, which is important during embryonic development, tissue morphogenesis, and for the removal of unwanted or damaged cells in our body [<xref rid="B30-ijms-20-00372" ref-type="bibr">30</xref>]. There are two common types of PCD, namely, apoptosis (Type I) (<xref ref-type="fig" rid="ijms-20-00372-f001">Figure 1</xref>) and autophagy (Type II) (<xref ref-type="fig" rid="ijms-20-00372-f002">Figure 2</xref>). In addition, it has recently been proposed that necrosis, which is more popularly known as an accidental cell death, could also be a form of PCD, known as necroptosis (Type III PCD). Dysregulation of these pathways is often captured during cancer development, rendering enhanced cell survival in cancer cells [<xref rid="B31-ijms-20-00372" ref-type="bibr">31</xref>]. Therefore, therapeutics that are able to provoke these mechanisms stand a chance to eliminate cancer cell population. Herein, evidences on the effects of tocotrienols toward PCD, particularly type I and type II PCD, are presented and discussed to provide a general landscape of different cell death modalities induced by tocotrienols.</p></sec><sec id="sec3-ijms-20-00372"><title>3. Tocotrienols Act as a Potent Apoptosis Inducer</title><p>Targeting apoptotic pathways remains an attractive approach to effectively eliminate cancer cells without causing inflammation. For many years, tocotrienols have been gaining immense research attention due to their proapoptotic effect in various types of cancers, as previously reported in breast [<xref rid="B38-ijms-20-00372" ref-type="bibr">38</xref>,<xref rid="B39-ijms-20-00372" ref-type="bibr">39</xref>], lung [<xref rid="B40-ijms-20-00372" ref-type="bibr">40</xref>], colon [<xref rid="B23-ijms-20-00372" ref-type="bibr">23</xref>,<xref rid="B41-ijms-20-00372" ref-type="bibr">41</xref>,<xref rid="B42-ijms-20-00372" ref-type="bibr">42</xref>], brain [<xref rid="B20-ijms-20-00372" ref-type="bibr">20</xref>,<xref rid="B43-ijms-20-00372" ref-type="bibr">43</xref>], liver [<xref rid="B44-ijms-20-00372" ref-type="bibr">44</xref>,<xref rid="B45-ijms-20-00372" ref-type="bibr">45</xref>], cervix [<xref rid="B46-ijms-20-00372" ref-type="bibr">46</xref>], blood [<xref rid="B47-ijms-20-00372" ref-type="bibr">47</xref>], and skin [<xref rid="B17-ijms-20-00372" ref-type="bibr">17</xref>,<xref rid="B48-ijms-20-00372" ref-type="bibr">48</xref>] cancers. Various apoptotic mechanisms triggered by tocotrienols are presented in this section.</p><sec id="sec3dot1-ijms-20-00372"><title>3.1. Tocotrienols Induce Mitochondria-Mediated Apoptosis</title><p>Mitochondria are tiny organelles in a cell, which exert both vital and lethal functions. In addition to serving as a powerhouse for fueling energy to cells, this organelle also contains homicidal molecules that can subject a cell to death [<xref rid="B49-ijms-20-00372" ref-type="bibr">49</xref>]. Tocotrienols exhibit mitochondrial disruption capacity via mitochondrial outer membrane permeabilization (MOMP) induction [<xref rid="B50-ijms-20-00372" ref-type="bibr">50</xref>,<xref rid="B51-ijms-20-00372" ref-type="bibr">51</xref>,<xref rid="B52-ijms-20-00372" ref-type="bibr">52</xref>], culminating in mitochondria-mediated apoptosis. In fact, MOMP is a critical event in the intrinsic apoptotic pathway. It has been reported that the blockade of mitochondrial permeability transition pore (MPTP) with cyclosporine A completely abolished the cytotoxic effects of TRF, &#x003b2;-T3, &#x003b3;-T3, and &#x003b4;-T3 in activated rat pancreatic stellate cells, which could support the growth and invasiveness of pancreatic ductal adenocarcinoma [<xref rid="B53-ijms-20-00372" ref-type="bibr">53</xref>,<xref rid="B54-ijms-20-00372" ref-type="bibr">54</xref>].</p><p>Although the actual role of tocotrienols in mitochondria-mediated apoptosis remains elusive, four potential interactions have been proposed (<xref ref-type="fig" rid="ijms-20-00372-f003">Figure 3</xref>). Several lines of evidence have reported that tocotrienols alter Bcl-2/Bax ratio, rendering depolarization of mitochondria [<xref rid="B50-ijms-20-00372" ref-type="bibr">50</xref>,<xref rid="B55-ijms-20-00372" ref-type="bibr">55</xref>,<xref rid="B56-ijms-20-00372" ref-type="bibr">56</xref>]. A study conducted on neuroblastoma SH-SY5Y cells shed a light on the potential interaction between &#x003b3;-T3 and B-cell lymphoma 2 (Bcl-2) proteins. This research showed that &#x003b3;-T3 competes with 8-Anilino-1-naphthalenesulfonic acid ammonium salt (ANS) for binding to the hydrophobic groove of Bcl-2. Hence, it was suggested that &#x003b3;-T3 acts as Bcl-2 homology 3 (BH3) mimetic to displace proapoptotic members from Bcl-2 sequestration. As a result, proapoptotic molecules become available to permeabilize the outer mitochondrial membrane and release cytochrome <italic>c</italic> to the cytosol, leading to caspase-9- and caspase-3-dependent apoptosis [<xref rid="B57-ijms-20-00372" ref-type="bibr">57</xref>]. However, it will be more worthwhile if &#x003b3;-T3, which is claimed to serve as an inhibitor of antiapoptotic Bcl-2 members, can be further characterized to allow development of derivatives that embrace a greater therapeutic efficacy [<xref rid="B57-ijms-20-00372" ref-type="bibr">57</xref>].</p><p>On the other hand, another study revealed that the elevated Bax expression induced by &#x003b4;-T3 correlates to the induction of zinc finger transcription factor, known as early growth response protein 1 (EGR1). This transcription factor binds to the <italic>Bax</italic> gene promoter, leading to the induction of proapoptotic Bax in pancreatic cancer cells [<xref rid="B58-ijms-20-00372" ref-type="bibr">58</xref>].</p><p>Suppression of inhibitor of apoptosis (IAP) could be another target of tocotrienols in mitochondrial pathway. IAP can block apoptosis by deactivating caspases activity. Interestingly, tocotrienols have been reported to be able to downregulate the IAP level, such as cIAP-1, cIAP2, and survivin in colorectal cancer [<xref rid="B59-ijms-20-00372" ref-type="bibr">59</xref>,<xref rid="B60-ijms-20-00372" ref-type="bibr">60</xref>]. Of note, cancer displays an elevated IAP profile to promote uncontrollable cell division, which may hinder the effectiveness of treatments that rely on caspase activation. Hence, the ability to block the activity of IAP could be an opportunity to culminate in a complete activation of apoptosis.</p><p>Other than indirectly modulating the Bcl-2 family to induce MOMP, &#x003b3;-T3-treated MDA-MB-231 breast cancer cells have been found to show a direct disruption of mitochondrial membrane potential independent from Bax/Bcl-2 ratio alteration and poly(ADP-ribose) polymerase (PARP) cleavage [<xref rid="B50-ijms-20-00372" ref-type="bibr">50</xref>]. The authors suggested that cytochrome <italic>c</italic> release is not a critical event for apoptosis induction in this scenario. In another study, &#x003b3;-T3 treatment on human T cell lymphoma Jurkat cells elevated mitochondrial reactive oxidative species (ROS) production [<xref rid="B61-ijms-20-00372" ref-type="bibr">61</xref>]. Hence, it is plausible to suggest that &#x003b3;-T3 could promote mitochondrial dysfunction, probably via ROS generation, leading to metabolic catastrophe and cell death, rather than engaging caspase-dependent intrinsic apoptosis. Additionally, it can also be speculated that &#x003b3;-T3 induces caspase-independent cell death following the release of soluble intermembrane mitochondrial proteins, such as apoptosis inducing factor (AIF) [<xref rid="B50-ijms-20-00372" ref-type="bibr">50</xref>], high temperature requirement A (HtrA), and endonuclease G (EndoG).</p></sec><sec id="sec3dot2-ijms-20-00372"><title>3.2. Tocotrienols Induce Endoplasmic Reticulum Stress</title><p>Endoplasmic reticulum (ER) experiences stress during perturbations in Ca<sup>2+</sup> homeostasis, redox imbalance, altered protein glycosylation, or protein folding defects, leading to accumulation of unfolded or misfolded proteins in the ER lumen [<xref rid="B62-ijms-20-00372" ref-type="bibr">62</xref>,<xref rid="B63-ijms-20-00372" ref-type="bibr">63</xref>]. Eventually, the highly conserved unfolded protein response (UPR) pathway is triggered to alleviate the potentially toxic stress and restore the homeostasis [<xref rid="B64-ijms-20-00372" ref-type="bibr">64</xref>]. A persistent and overwhelming ER stress will lead to apoptosis. Several studies have reported that tocotrienols exert ER stress as one of the mechanisms to induce apoptosis [<xref rid="B65-ijms-20-00372" ref-type="bibr">65</xref>,<xref rid="B66-ijms-20-00372" ref-type="bibr">66</xref>,<xref rid="B67-ijms-20-00372" ref-type="bibr">67</xref>]. In this section, the evidences of tocotrienols-induced ER stress are gathered and aligned to the present understanding on apoptosis that is led by ER stress (<xref ref-type="fig" rid="ijms-20-00372-f004">Figure 4</xref>).</p><p>The involvement of ER-stress-mediated apoptosis, as triggered by tocotrienols, was first reported by Wali and co-workers [<xref rid="B68-ijms-20-00372" ref-type="bibr">68</xref>]. Their work showed that &#x003b3;-T3 activated protein kinase-like endoplasmic reticulum kinase (PERK) arm of the UPR in neoplastic mouse +SA mammary epithelial cells by phosphorylating (inhibition) eukaryotic translational initiation factor (eIF2&#x003b1;), leading to the increase in activating transcription factor 4 (ATF-4) [<xref rid="B68-ijms-20-00372" ref-type="bibr">68</xref>]. Following that, the ER-stress-inducible nuclear protein, CCAAT-enhancer-binding protein homologous protein (CHOP), and tribbles 3 (TRB3) expressions were also increased. Knockdown of CHOP by siRNAs attenuated PARP cleavage induced by &#x003b3;-T3, suggesting a CHOP-dependent, ER-stress-mediated apoptosis.</p><p>Another study conducted on &#x003b3;-T3-treated MCF-7 and MDA-MB-231 breast cancer cells demonstrated an involvement of ER stress via both the PERK and inositol-requiring enzyme 1 (IRE1) pathways [<xref rid="B69-ijms-20-00372" ref-type="bibr">69</xref>], leading to remarkable increment in their downstream targets, such as activating transcription factor 3 (ATF3) and CHOP, in response to &#x003b3;-T3 treatment [<xref rid="B69-ijms-20-00372" ref-type="bibr">69</xref>]. The resultant apoptosis was evident by caspase-7 activation and PARP cleavage. In addition, ATF3 knockdown using siRNA abrogated the apoptosis, suggesting that ATF3 is a putative molecular target in &#x003b3;-T3-induced apoptosis [<xref rid="B69-ijms-20-00372" ref-type="bibr">69</xref>].</p><p>In HeLa cervical cancer cell line, &#x003b3;-T3 and &#x003b4;-T3 induces ER stress via the activation of IRE1 pathway, which in turn mediates the alternative splicing of X-box binding protein 1 (XBP-1) mRNA and modulates CHOP transcription [<xref rid="B70-ijms-20-00372" ref-type="bibr">70</xref>], leading to subsequent activation of caspase-9, -8, and -12 [<xref rid="B70-ijms-20-00372" ref-type="bibr">70</xref>]. In an attempt to study the underlying molecular mechanism, a specific estrogen receptor inhibitor (fulvestrant) employed as a competitive inhibitor to tocotrienols showed a reduction in the expression of proapoptotic genes [<xref rid="B70-ijms-20-00372" ref-type="bibr">70</xref>]. Hence, it was hypothesized that &#x003b3;-T3 may activate the &#x0201c;orphan&#x0201d; receptor (that also binds to fulvestrant), leading to IRE-1 activation and XBP-1 splicing, which finally induce apoptosis that is cognate with the activation of ER stress.</p><p>To our knowledge, the involvement of ATF6 pathway was reported as null in at least two studies [<xref rid="B69-ijms-20-00372" ref-type="bibr">69</xref>,<xref rid="B71-ijms-20-00372" ref-type="bibr">71</xref>]. Differing from PERK and IRE pathways, the activation of ATF6 requires translocation and cleavage in Golgi apparatus, which is often associated with enhanced survival in cancer cells [<xref rid="B69-ijms-20-00372" ref-type="bibr">69</xref>,<xref rid="B72-ijms-20-00372" ref-type="bibr">72</xref>]. It is possible that tocotrienols-induced ER stress is rapid and favors apoptosis, leaving behind the prosurvival option. Although a reduction of ATF6&#x003b1; level has been observed in +SA cells, the spatial information in relation to its cleavage has not been studied [<xref rid="B68-ijms-20-00372" ref-type="bibr">68</xref>]. Possibly, the ATF6 level reduction is due to cell death but not cleavage in the Golgi apparatus. Hence, the involvement of ATF6 pathway in tocotrienols-induced ER-stress-mediated apoptosis requires further investigation.</p><p>The activation of extrinsic apoptotic pathway being coupled to ER stress suggests a close connection between them. For instance, it has been reported that both death receptor 5 and CHOP were upregulated upon treatment of &#x003b3;-T3 on MDA-MB-231 and MCF-7 breast cancer cells [<xref rid="B73-ijms-20-00372" ref-type="bibr">73</xref>]. However, the sequence of activation and the dominance of the respective pathways remain elusive.</p></sec><sec id="sec3dot3-ijms-20-00372"><title>3.3. Co-Involvement of Endoplasmic Reticulum Stress and Mitochondria-Mediated Apoptosis</title><p>The interconnectivity between organelles could play an important role in perceiving stress upon receiving cancer drugs and influences the life or death decision in the cancer cells. In fact, increasing evidences have shown that ER stress may cooperate with mitochondria for stress signal amplification, thus culminating in apoptosis [<xref rid="B74-ijms-20-00372" ref-type="bibr">74</xref>]. For instance, mitochondria-mediated apoptosis was evident in &#x003b4;-T3-treated BLM and A375 human melanoma cell lines by cytochrome <italic>c</italic> release and augmentation of Bax/Bcl-2 ratio. At the same time, ER-stress-related proteins, such as PERK, p-eIF2&#x003b1;, ATF4, CHOP, IRE1&#x003b1;, and caspase-4, were activated. The application of salubrinal (inhibitor of ER stress) has been found to successfully block the cytotoxicity of &#x003b4;-T3, signifying the importance of ER stress for apoptosis induction [<xref rid="B71-ijms-20-00372" ref-type="bibr">71</xref>]. In fact, ATF/CHOP or IRE-1 ER stress sensors could be the mediators to connect ER stress to mitochondrial pathway of apoptosis [<xref rid="B75-ijms-20-00372" ref-type="bibr">75</xref>], potentially via the modulation of Bcl-2 family [<xref rid="B76-ijms-20-00372" ref-type="bibr">76</xref>]. It is interesting to note that several studies have suggested ATF4 may facilitate the transcriptional upregulation of BH3-only proteins, such as p53 upregulating the modulator of apoptosis (PUMA) and NOXA during ER stress [<xref rid="B77-ijms-20-00372" ref-type="bibr">77</xref>,<xref rid="B78-ijms-20-00372" ref-type="bibr">78</xref>,<xref rid="B79-ijms-20-00372" ref-type="bibr">79</xref>]. On the other hand, CHOP also downregulates Bcl-2 protein, thus incurring higher susceptibility to MOMP [<xref rid="B77-ijms-20-00372" ref-type="bibr">77</xref>]. Additionally, it appears that calcium signaling could play an important role in the ER&#x02013;mitochondrial communication [<xref rid="B76-ijms-20-00372" ref-type="bibr">76</xref>]. It has been suggested that the elevated flux of Ca<sup>2+</sup> from ER, subsequently leading to cytochrome <italic>c</italic> release, could happen independent of MPTP [<xref rid="B77-ijms-20-00372" ref-type="bibr">77</xref>]. Thus far, only limited studies have been conducted on understanding the connectivity of tocotrienols-induced ER stress and mitochondria-mediated apoptosis. Time course studies on molecular targets for both pathways can be conducted in order to elucidate the superiority of each pathway in tocotrienols-induced apoptosis, which may offer a better understanding on the mechanism of action and pave an avenue for discovering novel therapeutics for cancers.</p></sec><sec id="sec3dot4-ijms-20-00372"><title>3.4. Co-Involvement of Extrinsic and Intrinsic Pathways</title><p>In addition to tocotrienols inducing apoptosis via intrinsic mitochondrial pathway, a few studies have shown that both intrinsic and extrinsic pathways are activated concurrently. Although death-receptor-mediated extrinsic pathway and mitochondria-mediated intrinsic pathway are triggered by different stimuli, the two pathways are converged on executioner caspases (e.g., caspase-3, -7). &#x003b3;-T3 has been reported to engage both intrinsic and extrinsic pathways in Hep3B human hepatoma cells, as demonstrated by elevated activities of caspase-8, -9, -3 and accompanied by upregulation of truncated Bid and Bax, resulting in PARP cleavage [<xref rid="B45-ijms-20-00372" ref-type="bibr">45</xref>]. In addition, co-elicitation of intrinsic pathway by inducing Ca<sup>2+</sup> release, loss of mitochondrial membrane potential, and increase in Bax/Bcl-2 ratio, and extrinsic pathway via upregulating surface expression of Fas and FasL in &#x003b3;-T3-treated human T-cell lymphoma (Jurkat cells) has been reported. Eventually, apoptosis was induced via activation of caspase-8, -9, and -3 and PARP cleavage [<xref rid="B61-ijms-20-00372" ref-type="bibr">61</xref>]. Moreover, the involvement of Bid, Bax, cytochrome <italic>c</italic>, disruption of mitochondrial membrane permeabilization-dependent caspase-8 activation induced by &#x003b1;-T3, &#x003b3;-T3, and &#x003b4;-T3 have also been reported in A549 lung adenocarcinoma and U87MG brain glioblastoma [<xref rid="B40-ijms-20-00372" ref-type="bibr">40</xref>]. In addition, activation of both intrinsic and extrinsic pathways has been reported in leukemic cells, involving upregulation of genes in Bcl-2, caspases, and death receptor families [<xref rid="B80-ijms-20-00372" ref-type="bibr">80</xref>]. These evidences therefore suggest a convergence of extrinsic and intrinsic pathways at mitochondria, which potentially serve as an apoptosis signal amplification center. The cooperative interaction by simultaneous activation of intrinsic and extrinsic pathways can potentially lead to enhanced cell death through functional complementation as mutation of more than one pathway is common in cancer [<xref rid="B65-ijms-20-00372" ref-type="bibr">65</xref>,<xref rid="B81-ijms-20-00372" ref-type="bibr">81</xref>]. However, the benefit of this cooperative action induced by tocotrienols may be more remarkable in type II cancer cells, which requires mitochondrial pathway for death-receptor-induced apoptosis [<xref rid="B82-ijms-20-00372" ref-type="bibr">82</xref>].</p></sec></sec><sec id="sec4-ijms-20-00372"><title>4. Interplay between Autophagy and Apoptosis</title><p>Autophagy has been well known as a mechanism for cell survival under immense cell stress, whereas apoptosis is a pro-death decision when a cell experiences an unrecoverable damage. Therefore, inhibition of autophagy is often seen as an approach to promote apoptosis. For instance, a study showed that application of autophagy inhibitor 3-methyladenine (3-MA) potentiated apoptosis induced by dietary tocotrienols in breast cancer cells [<xref rid="B83-ijms-20-00372" ref-type="bibr">83</xref>], suggesting an antagonistic role of autophagy to apoptosis.</p><p>On the contrary, accumulating evidences have shown that autophagy and apoptosis act together to induce cell death in cancer. However, the connections at molecular level are multifaceted and poorly understood [<xref rid="B84-ijms-20-00372" ref-type="bibr">84</xref>]. We attempt to establish a connection between tocotrienols-induced apoptosis and autophagy based on currently available literature (<xref ref-type="fig" rid="ijms-20-00372-f005">Figure 5</xref>). Mitochondria and ER are proposed as the target organelles to drive the connection between the two pathways.</p><p>The activated pancreatic stellate cells treated with TRF exhibit the ability of tocotrienols to co-induce mitochondria-mediated apoptosis and autophagy [<xref rid="B53-ijms-20-00372" ref-type="bibr">53</xref>]. In the study, TRF was reported to cause apoptosis, as indicated by depolarized mitochondrial membrane, cytochrome <italic>c</italic> release, increased DNA fragmentation, and caspase activation. Concurrently, autophagy was also apparent by the formation of autophagic vacuoles and LC3-II accumulation. An attempt to block apoptosis with zVAD-fmk caspase inhibitor showed a converse enhancement in autophagy, suggesting autophagy could serve as a backup plan to execute the cells when apoptosis fails. In this case, autophagy is engaged in an immediate and active process, rather than as a passive &#x0201c;stress adaptive&#x0201d; function. It has been proposed that tocotrienols interconnect apoptosis and autophagy at mitochondria because the blockade of MPTP with cyclosporine A completely abolishes apoptosis and autophagic response [<xref rid="B85-ijms-20-00372" ref-type="bibr">85</xref>].</p><p>The actual mechanism has not been fully elucidated; however, it has been suggested that tocotrienols may initiate intrinsic mitochondrial pathway by displacing proapoptotic (Bax, Bak, BH3-only proteins) and proautophagic (Beclin-1) proteins from BH3 docking sites of Bcl-2 or Bcl-xL proteins, resulting in both apoptosis and autophagy [<xref rid="B85-ijms-20-00372" ref-type="bibr">85</xref>]. In addition, ROS generated from compromised mitochondria by TRF treatment has been proposed to connect two pathways because ROS is essential to activate autophagic enzymes, such as Atg4 [<xref rid="B85-ijms-20-00372" ref-type="bibr">85</xref>], as well as to amplify apoptotic signal. Although this study was not developed from a cancer model, the dual pathways activation shed a light on the novel function of tocotrienols. Later, concurrent activation of apoptosis and autophagy was correspondingly reported in other cancer cell lines, such as breast and prostate [<xref rid="B86-ijms-20-00372" ref-type="bibr">86</xref>,<xref rid="B87-ijms-20-00372" ref-type="bibr">87</xref>].</p><p>In &#x003b3;-T3-treated mouse (+SA) mammary tumor cells and human (MCF-7 and MDA-MD-231) breast cancer cell lines, proautophagic proteins, such as LC3-II/LC3-I ratio and Beclin-1 levels, and the corresponding increased levels of apoptotic markers including Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved PARP, demonstrated the concurrent induction of autophagy and apoptosis [<xref rid="B88-ijms-20-00372" ref-type="bibr">88</xref>]. In the following study, the authors showed autophagy inhibitor surrogating the cytotoxicity [<xref rid="B89-ijms-20-00372" ref-type="bibr">89</xref>], further confirming the presence of cytotoxic autophagic cell death. In prostate cancer cells, &#x003b3;-T3 induced elevated intracellular ceramides (dihydrosphingosine and dihydroceramide), which appear to be potent mediators of apoptosis and autophagy [<xref rid="B87-ijms-20-00372" ref-type="bibr">87</xref>]. Ceramides have been well reported as a key player in apoptosis by inducing both intrinsic and extrinsic apoptotic pathways [<xref rid="B90-ijms-20-00372" ref-type="bibr">90</xref>]. In comparison, the connection of ceramides with autophagy is emerging; the ceramides may activate c-Jun N-terminal 1 (JNK1) to phosphorylate Bcl-2 (inactivation), eventually leading to the dissociation of Beclin-1 from Bcl-2 [<xref rid="B90-ijms-20-00372" ref-type="bibr">90</xref>].</p><p>In addition, &#x003b3;-T3 can simultaneously activate ER-stress-mediated apoptosis and autophagy to promote cell death in MCF-7 and MDA-MB-231 breast cancer cells [<xref rid="B89-ijms-20-00372" ref-type="bibr">89</xref>]. Autophagy markers, such as Beclin-1, LC3-II, lysosomal-associated membrane protein 1 (LAMP-1), and cathepsin-D, were upregulated in both breast cancer cell lines. Concurrently, ER stress apoptotic markers, such as phospho-PERK, phospho-eIF2&#x003b1;, BiP, IRE1&#x003b1;, ATF-4, CHOP, and TRB3, were upregulated, suggesting an involvement of ER-stress-mediated apoptosis and autophagy induction [<xref rid="B89-ijms-20-00372" ref-type="bibr">89</xref>]. Based on recent evidences, it can be speculated that ER stress induces Ca<sup>2+</sup> release into cytosol, which could serve as a second messenger to co-activate apoptosis and autophagy [<xref rid="B89-ijms-20-00372" ref-type="bibr">89</xref>,<xref rid="B90-ijms-20-00372" ref-type="bibr">90</xref>,<xref rid="B91-ijms-20-00372" ref-type="bibr">91</xref>]. Potentially, ER-stress-induced IRE1&#x003b1; stimulates JNK and p38 signaling, leading to inactivation of Bcl-2, as mentioned in the previous paragraph.</p></sec><sec id="sec5-ijms-20-00372"><title>5. Tocotrienols Target Prosurvival Signaling Pathways</title><p>Targeting only the cell death pathways may not be sufficient to eliminate cancer cells. Cell death signaling can be overcome by stimulation of cell survival via alternative modes, leading to a more complicated problem, such as development of drug-resistant cancer cells. Tocotrienols have been previously reported to concurrently activate cell death programs and downregulate prosurvival signaling pathways, such as nuclear factor kappa B (NF-&#x003ba;B), phosphoinositide 3-kinase (PI3K)/Akt, Wingless and INT-1 (Wnt), and mitogen-activated protein kinases (MAPKs) (<xref ref-type="fig" rid="ijms-20-00372-f006">Figure 6</xref>). Therefore, the following section describes the capability of tocotrienols in targeting cell survival and deliberating implications in the cell death mechanisms.</p><sec id="sec5dot1-ijms-20-00372"><title>5.1. NF-&#x003ba;B Family</title><p>The NF-&#x003ba;B activity is crucial in modulating survival-promoting proteins, which would lead to poor responses toward anticancer therapies. Inhibition of NF-&#x003ba;B by tocotrienols has been reported to reduce the expression of various proteins linked to cell survival, such as antiapoptosis (e.g., Bcl-2, Bcl-xL, cFLIP, IAP-1, IAP-2, XIAP, Bfl-1/A1, TRAF1, and survivin), proliferation (e.g., c-Myc and cyclin D1), inflammation (COX-2, cytokines), invasion (e.g., MMP-9, ICAM-1, ELAM-1, and VCAM-1), and neoangiogenesis (e.g., VEGF) [<xref rid="B92-ijms-20-00372" ref-type="bibr">92</xref>,<xref rid="B93-ijms-20-00372" ref-type="bibr">93</xref>,<xref rid="B94-ijms-20-00372" ref-type="bibr">94</xref>]. Tocotrienols have been shown to reduce constitutive NF-&#x003ba;B activity in mammary epithelial [<xref rid="B95-ijms-20-00372" ref-type="bibr">95</xref>], prostate cancer [<xref rid="B19-ijms-20-00372" ref-type="bibr">19</xref>], multiple myeloma [<xref rid="B92-ijms-20-00372" ref-type="bibr">92</xref>], lung adenocarcinoma [<xref rid="B96-ijms-20-00372" ref-type="bibr">96</xref>], oral cancer [<xref rid="B97-ijms-20-00372" ref-type="bibr">97</xref>], and colon carcinoma [<xref rid="B56-ijms-20-00372" ref-type="bibr">56</xref>] cell lines. A study conducted on pancreatic cancer showed that &#x003b3;-T3 was able to suppress NF-&#x003ba;B activity in vitro and in vivo [<xref rid="B98-ijms-20-00372" ref-type="bibr">98</xref>]. Correspondingly, &#x003b4;-T3 significantly affected NF-&#x003ba;B DNA binding activity in pancreatic cancer cells [<xref rid="B99-ijms-20-00372" ref-type="bibr">99</xref>]. This inhibitory activity appears to be exclusive for &#x003b3;-T3 and &#x003b4;-T3 isomers as &#x003b1;-T3 and &#x003b2;-T3 had no significant effect on NF-&#x003ba;B activity [<xref rid="B99-ijms-20-00372" ref-type="bibr">99</xref>]. It has been proposed that &#x003b3;-T3 and &#x003b4;-T3 block the phosphorylation and degradation of I&#x003ba;B (inhibitor of NF-&#x003ba;B), leading to inhibition of I&#x003ba;B kinase (IKK) complex activation as well as suppression of nuclear translocation of p65 [<xref rid="B18-ijms-20-00372" ref-type="bibr">18</xref>,<xref rid="B92-ijms-20-00372" ref-type="bibr">92</xref>,<xref rid="B99-ijms-20-00372" ref-type="bibr">99</xref>]. Another in vivo study combining &#x003b3;-T3 with capecitabine also demonstrated a significant inhibition in NF-&#x003ba;B and NF-&#x003ba;B-regulated proteins, such as cyclin D1, COX-2, MMP-9, ICAM-1, Bcl-xL, survivin, and XIAP, in gastric tumor tissues [<xref rid="B100-ijms-20-00372" ref-type="bibr">100</xref>]. As a result, the blocking of NF-&#x003ba;B pathway leads to the suppression of antiapoptotic gene products and potentiation of apoptosis [<xref rid="B92-ijms-20-00372" ref-type="bibr">92</xref>]. Considering that apoptotic products are closely related to NF-&#x003ba;B activity, agents that can reduce the NF-&#x003ba;B level could serve as a potential &#x0201c;multitasking agent&#x0201d;.</p></sec><sec id="sec5dot2-ijms-20-00372"><title>5.2. PI3K/Akt Signaling</title><p>The PI3K pathway plays a determining role in regulating cell survival. The activation of Akt phosphorylates and inhibits the proapoptotic Bcl-2 family members, such as Bad [<xref rid="B101-ijms-20-00372" ref-type="bibr">101</xref>]. The antiproliferative effect of &#x003b3;-T3 in neoplastic +SA mouse mammary epithelial cells is mediated by a reduction in PI3K/PDK-1/Akt mitogenic signaling [<xref rid="B102-ijms-20-00372" ref-type="bibr">102</xref>]. Suppression in this signaling pathway further leads to death-receptor-independent caspase-8 activation and reduction of intracellular FLIP expression [<xref rid="B103-ijms-20-00372" ref-type="bibr">103</xref>,<xref rid="B104-ijms-20-00372" ref-type="bibr">104</xref>]. In pancreatic cancer cell lines (MIA PaCa-2 and Panc-28), &#x003b3;-T3 and &#x003b4;-T3 could effectively prevent Akt activation. A further study revealed that several downstream targets of Akt were affected by &#x003b3;-T3, such as mTOR, S6 kinase (Ser 240/244), GSK-3&#x003b2;, and FOXO3 [<xref rid="B105-ijms-20-00372" ref-type="bibr">105</xref>]. These results collectively suggest that the two tocotrienol isoforms can induce apoptosis in pancreatic cancer cells through the suppression of vital cell survival and proliferative signaling pathways [<xref rid="B105-ijms-20-00372" ref-type="bibr">105</xref>].</p></sec><sec id="sec5dot3-ijms-20-00372"><title>5.3. MAP Kinase Signaling</title><p>MAPK signaling pathway plays a critical role in the outcome of, and sensitivity to anticancer therapies [<xref rid="B106-ijms-20-00372" ref-type="bibr">106</xref>]. There are three important MAPK members for maintenance of cells, namely, extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38-MAPKs. ERKs have been found to be important for cell survival, whereas JNKs are deemed stress-responsive and thus involved in apoptosis [<xref rid="B107-ijms-20-00372" ref-type="bibr">107</xref>]. On the other hand, p38-MAPK has been reported to exhibit a dual role as cell death and cell survival regulators depending on the types of cell and stimulus received [<xref rid="B108-ijms-20-00372" ref-type="bibr">108</xref>]. Of note, it has been proposed that the roles of p38 and JNK regulate the balance of apoptosis and autophagy in response to chemotherapeutic agents, portraying a significant role of MAPK signaling in deciding life or death matter.</p><p>&#x003b3;-T3 and &#x003b4;-T3 treatments in pancreatic cells have been found to show reductions of ERK activation and its downstream mediator RSK (ribosomal protein S6 kinase), which correlate to the downregulation of HER/ErbB2 expression [<xref rid="B105-ijms-20-00372" ref-type="bibr">105</xref>]. On the other hand, a research illustrated that &#x003b3;-T3 treatment caused suppressions of ERK and p38 MAPK but an activation of ERK in T-cell lymphoma, leading to both intrinsic and extrinsic apoptosis [<xref rid="B61-ijms-20-00372" ref-type="bibr">61</xref>]. In contrast, another study reported that &#x003b3;-T3 elevated death receptors, DR4, and DR5, which are regulated through ERK activation [<xref rid="B60-ijms-20-00372" ref-type="bibr">60</xref>]. In fact, the contradictory roles of ERK activation for promoting cell death or cell survival could be delineated by studying the subcellular localization of ERK proteins [<xref rid="B109-ijms-20-00372" ref-type="bibr">109</xref>]. For instance, translocation of ERK1/2 to nucleus carries an anticancer role, while positioning to mitochondria may promote cell survival [<xref rid="B110-ijms-20-00372" ref-type="bibr">110</xref>]. Collectively, these studies reveal a connection between proliferative signaling and apoptosis, which further strengthens the versatility of tocotrienols in targeting cancers.</p></sec><sec id="sec5dot4-ijms-20-00372"><title>5.4. Wnt Signaling</title><p>Wnt signaling is one of the key cascades for regulating development and stemness; overactivation of this pathway commonly occurs in cancer, predominantly in colorectal cancer [<xref rid="B111-ijms-20-00372" ref-type="bibr">111</xref>]. Wnt pathway is commonly divided into canonical (&#x003b2;-catenin-dependent) and noncanonical (&#x003b2;-catenin-independent) signaling [<xref rid="B111-ijms-20-00372" ref-type="bibr">111</xref>]. Serving as an important driver in the canonical pathway, the activation of Wnt receptors leads to translocation of &#x003b2;-catenin into nucleus. Subsequently, it forms an active complex with lymphoid enhancer factor (LEF), T-cell factor (TCF), and histone-modifying coactivators to initiate transcriptional activities for multiple processes such as cell proliferation and cell survival, such as c-Myc, cyclin D1, and survivin [<xref rid="B111-ijms-20-00372" ref-type="bibr">111</xref>,<xref rid="B112-ijms-20-00372" ref-type="bibr">112</xref>]. Additional evidence has shown that activation of Wnt signaling can overcome the apoptosis mediated by Notch in gastric cancer [<xref rid="B113-ijms-20-00372" ref-type="bibr">113</xref>], portraying the importance of Wnt signaling in shaping apoptotic cell death.</p><p>&#x003b4;-T3 has been reported to inhibit SW620 colon cancer cells by downregulating the expression levels of Wnt-1, &#x003b2;-catenin, c-Jun, and cyclin D1 in the Wnt signal pathway [<xref rid="B114-ijms-20-00372" ref-type="bibr">114</xref>]. In addition, &#x003b3;-T3 inhibited cell viability through suppression of &#x003b2;-catenin/TCF signaling in human colon carcinoma HT-29 cells [<xref rid="B42-ijms-20-00372" ref-type="bibr">42</xref>]. TRF suppressed the growth of human colon cancer xenografts in Balb/c nude mice via the Wnt pathway, by which the expressions of &#x003b2;-catenin, Wnt, and c-Myc proteins in xenografts were significantly downregulated [<xref rid="B23-ijms-20-00372" ref-type="bibr">23</xref>]. In breast cancer cells, &#x003b3;-T3 reversed the epithelial-to-mesenchymal transition in human breast cancer via the inhibition of canonical Wnt signaling [<xref rid="B115-ijms-20-00372" ref-type="bibr">115</xref>]. Taken together, the ability of tocotrienols in targeting Wnt pathway suggests a value-added therapy to effectively regulate proliferation, apoptosis, and metastasis simultaneously.</p></sec></sec><sec id="sec6-ijms-20-00372"><title>6. Current and Future Perspectives of Tocotrienols</title><p>To date, undoubtedly, promising anticancer effects and molecular targets of tocotrienols in promoting cell death and suppressing survival in cancers have been revealed from numerous in vitro (<xref rid="ijms-20-00372-t001" ref-type="table">Table 1</xref>) and in vivo (<xref rid="ijms-20-00372-t002" ref-type="table">Table 2</xref>) studies. These valuable preclinical findings have expectedly warranted further investigations for clinical applications, some recent examples of which are summarized in <xref rid="ijms-20-00372-t003" ref-type="table">Table 3</xref>. Despite ample evidence of the therapeutic benefits of tocotrienols in various types of cancers, current clinical studies have only embarked on breast, colon, pancreas, lung, and ovary cancers. Other cancer types, such as brain, blood, gastric, and prostate cancers, with positive therapeutic potentials may be lining up in forthcoming clinical trials.</p><p>Yet, poor oral bioavailability remains the main hurdle limiting the in vivo therapeutic efficacy of tocotrienols. Saturable uptake in the transport mechanism within intestine and bloodstream, leading to low bioavailability, has therefore greatly compromised the efficacy and potency of tocotrienols via oral intake [<xref rid="B116-ijms-20-00372" ref-type="bibr">116</xref>]. Several formulation strategies have been found to enhance the oral absorption of tocotrienols by at least 3 folds, including self-emulsifying delivery systems [<xref rid="B117-ijms-20-00372" ref-type="bibr">117</xref>] and nanostructured lipid carriers [<xref rid="B118-ijms-20-00372" ref-type="bibr">118</xref>]. In addition, alternative routes of administration have been investigated to circumvent the limitations associated with oral absorption. One such approach is the application of nanoformulation that enables tocotrienols to be administered via intravenous and topical routes. Polymer-conjugated tocotrienols [<xref rid="B119-ijms-20-00372" ref-type="bibr">119</xref>] and entrapment of tocotrienols in nanovesicles [<xref rid="B120-ijms-20-00372" ref-type="bibr">120</xref>] have been investigated for intravenous injection, while tocotrienol nanoemulsions have been investigated for topical applications [<xref rid="B121-ijms-20-00372" ref-type="bibr">121</xref>]. These formulations markedly improved the antiproliferative activities of tocotrienols in vitro and tumor suppression properties in vivo. Hence, further studies on clinical translation of these novel tocotrienol formulations are warranted.</p><p>It has been widely reported that administration of high-dose tocotrienols is a futile maneuver due to high metabolic degradation in vivo [<xref rid="B43-ijms-20-00372" ref-type="bibr">43</xref>]. Prominently, the hypomethylated forms of tocotrienols, i.e., &#x003b4;-T3 and &#x003b3;-T3, show the highest cellular metabolism. In fact, high metabolism of T3s in vivo are associated with the induction of drug metabolizing enzymes, such as cytochrome P450 enzyme (CYP450) and glucuronosyltransferase 1A1 (UGT1A1) as well as the induction of multidrug resistance protein-1 (MDR1) via pregame-X-receptor (PXR) and steroid and xenobiotic receptor (SXR). These enzymes appear to deliver positive cytotoxic effects to cancer cells; however, coadministration of high-dose tocotrienols with other drugs may potentially interfere the metabolism, thereby affecting the therapeutic efficacy of these drugs [<xref rid="B122-ijms-20-00372" ref-type="bibr">122</xref>,<xref rid="B123-ijms-20-00372" ref-type="bibr">123</xref>,<xref rid="B124-ijms-20-00372" ref-type="bibr">124</xref>]. Hence, a synergistic combination of tocotrienols with other anticancer agents at low doses can augment the therapeutic efficacy and potency (both bioactives) as well as reduce the dose-limiting toxicities (i.e., chemotherapeutic agents). In addition, a combined treatment approach could reduce the risk of developing drug resistance in cancer cells. As &#x0201c;one drug one target&#x0201d;-based targeted therapy (e.g., tyrosine kinase inhibitors) is inclined to drug resistance [<xref rid="B125-ijms-20-00372" ref-type="bibr">125</xref>], combinatorial application of tocotrienols that concurrently targets multiple signaling pathways can effectively eradicate cancer cell population [<xref rid="B126-ijms-20-00372" ref-type="bibr">126</xref>]. In fact, the multitargeted anticancer actions offered by tocotrienols are regarded as a valuable feature that could potentially pave an avenue into polypharmacology, which advocates &#x0201c;one drug multiple targets&#x0201d; [<xref rid="B127-ijms-20-00372" ref-type="bibr">127</xref>]. Furthermore, combining existing drugs with tocotrienols could also serve as an immediate and cost-effective solution. So far, combination therapies using tocotrienols with traditional chemotherapeutics, plant bioactives, and targeted inhibitors have shown positive therapeutic responses in vitro and in vivo, as reviewed by Eitsuka et al. [<xref rid="B128-ijms-20-00372" ref-type="bibr">128</xref>]. However, metabolism, toxicities, and pharmacokinetics studies of combined treatments in vivo are still lacking, more investigations are therefore necessary to advance effective drug combinations toward a tangible clinical application in the near future.</p><p>At present, two completed clinical trials have demonstrated positive benefits of tocotrienols in cancer management. Although statistically insignificant due to limited sample size, the first clinical study conducted on breast cancer patients showed that TRF in combination with tamoxifen improved breast-cancer-specific survival compared to the tamoxifen group (NCT01157026) [<xref rid="B38-ijms-20-00372" ref-type="bibr">38</xref>]. The second clinical trial conducted on pancreatic ductal neoplasia patients reported that &#x003b4;-T3 was well tolerated by patients, while the tumor samples showed an elevated caspase-3 activity, suggesting an enhanced apoptosis due to &#x003b4;-T3 intervention (NCT00985777). Furthermore, another clinical study investigating the new formulation of &#x003b3;-&#x003b4;-T3 showed an enhanced bioavailability in healthy subjects (NCT01571921), undoubtedly heralding a great milestone for accelerating its application for cancer therapy. Of note, a number of clinical trials are currently in progress to study the anticancer effects of tocotrienols and/or in combination with other therapeutic agents (<xref rid="ijms-20-00372-t003" ref-type="table">Table 3</xref>). Specifically, interventions of tocotrienols are involved as neoadjuvant and adjuvant cancer treatments as well as health supplements [<xref rid="B129-ijms-20-00372" ref-type="bibr">129</xref>]. Taken together, these studies could provide a better understanding on clinical applications of tocotrienols with optimal benefits.</p><p>While clinical trials of tocotrienols are important to identify the therapeutic benefits in various types of cancer, mechanistic studies should also be extensively conducted in order to explore further potentials upon acquiring the putative underlying mechanisms of action. In particular, the potential of tocotrienols in inducing nonapoptotic cell death has not been well described and certainly deserves more research attention. For instance, paraptosis induced by &#x003b4;-T3 and &#x003b3;-T3 colon cancer cells have shed a light on caspase-independent cell death [<xref rid="B130-ijms-20-00372" ref-type="bibr">130</xref>,<xref rid="B131-ijms-20-00372" ref-type="bibr">131</xref>]. The authors also highlighted the potential involvement of mitochondria and ER in tocotrienols-induced paraptosis, which is worthwhile to be investigated further [<xref rid="B130-ijms-20-00372" ref-type="bibr">130</xref>]. In addition, the crosstalk between cell death signaling is important to provide an insight into the molecular mechanisms, which may be essential for striking a balance between cell survival and cell death as well as their role as targets for the development of novel therapeutic approaches [<xref rid="B132-ijms-20-00372" ref-type="bibr">132</xref>]. Hence, considerable attention should be given to understand the tocotrienols-induced molecular crosstalk to gain insights on the cancer-specific mode of action. Moreover, as we are moving into an era of cancer molecular profiling, a comprehensive mechanism of action could better translate tocotrienols in clinical practice via rational drug designs.</p></sec><sec id="sec7-ijms-20-00372"><title>7. Conclusions</title><p>Tocotrienols exhibit versatility in inducing cell death by modulating various mechanisms in cancers. Tocotrienols exhibit potent proapoptotic capacities by inducing mitochondria-mediated apoptosis and ER-stress-mediated apoptosis; this co-elicitation is believed to serve as an enhanced cancer-killing strategy. In fact, engagement of both extrinsic and intrinsic apoptotic pathways by tocotrienols could lead to a more effective cancer elimination, particularly in Type II cells, which require mitochondrial pathway in inducing apoptosis. Apart from that, proper modulation of cell survival signaling underscores a pivotal role in shaping the ultimate cancer cellular demise. Of note, autophagy appears to account for a better role in cell death than its classical association in &#x0201c;cell survival&#x0201d; to serve as a backup mechanism in tocotrienols-induced apoptosis. Overall, the pleiotropic effects of tocotrienols in inducing various cell death mechanisms while hampering the prosurvival pathways of cancer cells portray a value-added action in fighting cancers. Yet, the oral bioavailability and metabolic degradation associated with high dose have constrained the clinical applications of tocotrienols. Perhaps the ongoing advancements in nanoformulation and combined treatment approaches could outshine the current cancer regimens using tocotrienols to achieve better therapeutic outcomes.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank the Malaysia Toray Science Foundation and the Ministry of Higher Education Malaysia for supporting the first author in her PhD study. This material is based upon the work supported by the Malaysia Toray Science Foundation and the Malaysian Palm Oil Board.</p></ack><notes><title>Author Contributions</title><p>S.-Y.T. and H.-S.L. contributed to the conception of this paper. S.-Y.T. gathered data and prepared the original draft and schematic illustrations. J.-Y.F. drafted parts of the content in <xref ref-type="sec" rid="sec6-ijms-20-00372">Section 6</xref>. H.-S.L. conducted a critical revision of the written content and tabulated data. Final review and editing were conducted by H.-S.L., C.-W.M., and J.-Y.F. toward generating the paper as presented.</p></notes><notes><title>Funding</title><p>The project was funded by the Malaysia Toray Science Foundation and the Malaysian Palm Oil Board.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">3-MA</td><td align="left" valign="middle" rowspan="1" colspan="1">3-Methyladenine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ABCG2</td><td align="left" valign="middle" rowspan="1" colspan="1">ATP-binding cassette subfamily G member 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AIF</td><td align="left" valign="middle" rowspan="1" colspan="1">Apoptosis-inducing factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Akt</td><td align="left" valign="middle" rowspan="1" colspan="1">PKB or protein kinase B</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ANS</td><td align="left" valign="middle" rowspan="1" colspan="1">8-Anilino-1-naphthalenesulfonic acid ammonium salt</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Apaf-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Apoptotic protease activating factor 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">APC</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenomatous polyposis coli</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATF4</td><td align="left" valign="middle" rowspan="1" colspan="1">Activating transcription factor 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATF6</td><td align="left" valign="middle" rowspan="1" colspan="1">Activating transcription factor 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Atg</td><td align="left" valign="middle" rowspan="1" colspan="1">Autophagy-related protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bf1-1/A1</td><td align="left" valign="middle" rowspan="1" colspan="1">Bcl-2-related protein A1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BH3</td><td align="left" valign="middle" rowspan="1" colspan="1">Bcl-2 homology 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BiP</td><td align="left" valign="middle" rowspan="1" colspan="1">GRP78, glucose-regulated protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDK</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclin-dependent kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHOP</td><td align="left" valign="middle" rowspan="1" colspan="1">CCAAT-enhancer-binding protein homologous protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">cIAP</td><td align="left" valign="middle" rowspan="1" colspan="1">Cellular inhibitor of apoptosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COX-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclooxygenase-2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CXCR4</td><td align="left" valign="middle" rowspan="1" colspan="1">C-X-C motif chemokine receptor 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CYP450</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytochrome P450 enzyme </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DR</td><td align="left" valign="middle" rowspan="1" colspan="1">Death receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGR1</td><td align="left" valign="middle" rowspan="1" colspan="1">Early growth response protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">eIF2-&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">Eukaryotic initiation factor 2 alpha</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ELAM-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Endothelial cell adhesion molecule-2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EndoG</td><td align="left" valign="middle" rowspan="1" colspan="1">Endonuclease G</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ER</td><td align="left" valign="middle" rowspan="1" colspan="1">Endoplasmic reticulum</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ERK1/2</td><td align="left" valign="middle" rowspan="1" colspan="1">Extracellular signal-regulated protein kinases 1 and 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ERO1&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">Endoplasmic reticulum oxidation 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ETK1</td><td align="left" valign="middle" rowspan="1" colspan="1">Epithelial and endothelial tyrosine kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDFT1</td><td align="left" valign="middle" rowspan="1" colspan="1">Farnesyl-diphosphate farnesyltransferase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GSK-&#x003b2;</td><td align="left" valign="middle" rowspan="1" colspan="1">Glycogen synthase kinase 3 beta</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hes-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Hairy and enhancer of split-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hTERT</td><td align="left" valign="middle" rowspan="1" colspan="1">Human telomerase reverse transcriptase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HtrA</td><td align="left" valign="middle" rowspan="1" colspan="1">High temperature requirement A</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IAP</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibitor of apoptosis protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Intercellular adhesion molecules-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Id-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibitor of differentiation/DNA binding</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">I&#x003ba;B</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibitor of kappa B</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IKK&#x003b1;/&#x003b2;</td><td align="left" valign="middle" rowspan="1" colspan="1">I&#x003ba;B kinase alpha/beta</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-6</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IRE-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Inositol-requiring enzyme 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JNK</td><td align="left" valign="middle" rowspan="1" colspan="1">c-Jun N-terminal kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LAMP-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Lysosomal-associated membrane protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LC3</td><td align="left" valign="middle" rowspan="1" colspan="1">Microtubule-associated protein 1A/1B-light chain 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LRP</td><td align="left" valign="middle" rowspan="1" colspan="1">Low-density lipoprotein receptor-related protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAPK</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitogen-activated protein kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MC1R</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanocortin 1 receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mcl-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Myeloid cell leukemia 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDR1</td><td align="left" valign="middle" rowspan="1" colspan="1">Multidrug resistance protein-1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MEK</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitogen-activated protein kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MIC-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Macrophage inhibitory cytokine 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MITF</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanogenesis associated transcription factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMP</td><td align="left" valign="middle" rowspan="1" colspan="1">Matrix metalloproteinases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MOMP<break/>MPTP</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitochondrial outer membrane permeabilization<break/>Mitochondrial permeability transition pore</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mTOR</td><td align="left" valign="middle" rowspan="1" colspan="1">Mammalian target of rapamycin </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NF-&#x003ba;B</td><td align="left" valign="middle" rowspan="1" colspan="1">Nuclear factor kappa B</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Oct-4</td><td align="left" valign="middle" rowspan="1" colspan="1">Octamer-binding transcription factor 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p27Kip1</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclin-dependent kinase inhibitor 1B</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PARP</td><td align="left" valign="middle" rowspan="1" colspan="1">Poly(ADP-ribose) polymerase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCD</td><td align="left" valign="middle" rowspan="1" colspan="1">Programmed cell death</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Proliferating cell nuclear antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDK1</td><td align="left" valign="middle" rowspan="1" colspan="1">3-phosphoinositide-dependent protein kinase-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PERK</td><td align="left" valign="middle" rowspan="1" colspan="1">Protein kinase R (PKR)-like endoplasmic reticulum kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PI3K</td><td align="left" valign="middle" rowspan="1" colspan="1">Phosphoinositide 3-kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PXR</td><td align="left" valign="middle" rowspan="1" colspan="1">Pregame-X-receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">Reactive oxygen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RSK </td><td align="left" valign="middle" rowspan="1" colspan="1">Ribosomal protein S6 kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SAPK/JNK</td><td align="left" valign="middle" rowspan="1" colspan="1">Stress-activated protein kinase/c-Jun NH2-terminal kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SHP-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Src homology region 2 domain-containing phosphatase-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sox-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Sex determining region Y-box 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SXR</td><td align="left" valign="middle" rowspan="1" colspan="1">Steroid and xenobiotic receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x003b2;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Transforming growth factor beta 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TRA1</td><td align="left" valign="middle" rowspan="1" colspan="1">Transcription-associated protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TRB3</td><td align="left" valign="middle" rowspan="1" colspan="1">Tribbles-related Protein 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TYRP</td><td align="left" valign="middle" rowspan="1" colspan="1">Tyrosinase-related proteins</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UGT1A1</td><td align="left" valign="middle" rowspan="1" colspan="1">Glucuronosyltransferase 1A1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ULK</td><td align="left" valign="middle" rowspan="1" colspan="1">Unc-51-like kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">uPA</td><td align="left" valign="middle" rowspan="1" colspan="1">Urokinase-type plasminogen activator</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UPR</td><td align="left" valign="middle" rowspan="1" colspan="1">Unfolded protein response</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">US</td><td align="left" valign="middle" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VCAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Vascular cell adhesion molecule-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VEGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Vascular endothelial growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vps</td><td align="left" valign="middle" rowspan="1" colspan="1">Vacuolar protein sorting</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Wnt</td><td align="left" valign="middle" rowspan="1" colspan="1">Wingless/integrase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">XBP</td><td align="left" valign="middle" rowspan="1" colspan="1">X-box binding protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">XIAP</td><td align="left" valign="middle" rowspan="1" colspan="1">X-linked inhibitor of apoptosis protein</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-ijms-20-00372"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Soerjamataram</surname><given-names>I.</given-names></name><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Torrer</surname><given-names>L.A.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="B2-ijms-20-00372"><label>2.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Cancer Institute</collab></person-group><article-title>Cancer Statistics-National Cancer Institute</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/about-cancer/understanding/statistics">https://www.cancer.gov/about-cancer/understanding/statistics</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-12-18">(accessed on 18 December 2018)</date-in-citation></element-citation></ref><ref id="B3-ijms-20-00372"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>C.W.</given-names></name><name><surname>Chung</surname><given-names>F.F.L.</given-names></name><name><surname>Leong</surname><given-names>C.O.</given-names></name></person-group><article-title>Targeting legumain as a novel therapeutic strategy in cancers</article-title><source>Curr. Drug Targets</source><year>2017</year><volume>18</volume><pub-id pub-id-type="doi">10.2174/1389450117666161216125344</pub-id><?supplied-pmid 27993111?><pub-id pub-id-type="pmid">27993111</pub-id></element-citation></ref><ref id="B4-ijms-20-00372"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>C.W.</given-names></name><name><surname>Kang</surname><given-names>Y.B.</given-names></name><name><surname>Pichika</surname><given-names>M.R.</given-names></name></person-group><article-title>Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: Its expression and effects in the ten most common cancers</article-title><source>Onco-Targets Ther.</source><year>2013</year><volume>6</volume><fpage>1573</fpage><lpage>1587</lpage><?supplied-pmid 24235843?><pub-id pub-id-type="pmid">24235843</pub-id></element-citation></ref><ref id="B5-ijms-20-00372"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>F.F.L.</given-names></name><name><surname>Mai</surname><given-names>C.W.</given-names></name><name><surname>Ng</surname><given-names>P.Y.</given-names></name><name><surname>Leong</surname><given-names>C.O.</given-names></name></person-group><article-title>Cytochrome P450 2W1 (CYP2W1) in colorectal cancers</article-title><source>Curr. Cancer Drug Targets</source><year>2016</year><volume>16</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.2174/1568009616888151112095948</pub-id><?supplied-pmid 26563883?><pub-id pub-id-type="pmid">26563883</pub-id></element-citation></ref><ref id="B6-ijms-20-00372"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>C.W.</given-names></name><name><surname>Kang</surname><given-names>Y.B.</given-names></name><name><surname>Nadarajah</surname><given-names>V.D.</given-names></name><name><surname>Hamzah</surname><given-names>A.S.</given-names></name><name><surname>Pichika</surname><given-names>M.R.</given-names></name></person-group><article-title>Drug-like dietary vanilloids induce anticancer activity through proliferation inhibition and regulation of bcl-related apoptotic proteins</article-title><source>Phyther. Res.</source><year>2018</year><volume>32</volume><fpage>1108</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1002/ptr.6051</pub-id><?supplied-pmid 29464796?><pub-id pub-id-type="pmid">29464796</pub-id></element-citation></ref><ref id="B7-ijms-20-00372"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soo</surname><given-names>H.C.</given-names></name><name><surname>Chung</surname><given-names>F.F.L.</given-names></name><name><surname>Lim</surname><given-names>K.H.</given-names></name><name><surname>Yap</surname><given-names>V.A.</given-names></name><name><surname>Bradshaw</surname><given-names>T.D.</given-names></name><name><surname>Hii</surname><given-names>L.W.</given-names></name><name><surname>Tan</surname><given-names>S.H.</given-names></name><name><surname>See</surname><given-names>S.J.</given-names></name><name><surname>Tan</surname><given-names>Y.F.</given-names></name><name><surname>Leong</surname><given-names>C.O.</given-names></name><etal/></person-group><article-title>Cudraflavone C induces tumor-specific apoptosis in colorectal cancer cells through inhibition of the phosphoinositide 3-Kinase (PI3K)-AKT Pathway</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0170551</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0170551</pub-id><?supplied-pmid 28107519?><pub-id pub-id-type="pmid">28107519</pub-id></element-citation></ref><ref id="B8-ijms-20-00372"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>C.K.</given-names></name><name><surname>Hemaroopini</surname><given-names>S.</given-names></name><name><surname>Gan</surname><given-names>S.Y.</given-names></name><name><surname>Loo</surname><given-names>S.M.</given-names></name><name><surname>Low</surname><given-names>J.R.</given-names></name><name><surname>Jong</surname><given-names>V.Y.M.</given-names></name><name><surname>Soo</surname><given-names>H.C.</given-names></name><name><surname>Leong</surname><given-names>C.O.</given-names></name><name><surname>Mai</surname><given-names>C.W.</given-names></name><name><surname>Chee</surname><given-names>C.F.</given-names></name></person-group><article-title>In vitro cytotoxic activity of isolated compounds from Malaysian Calophyllum species</article-title><source>Med. Chem. Res.</source><year>2016</year><volume>25</volume><fpage>1686</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1007/s00044-016-1606-y</pub-id></element-citation></ref><ref id="B9-ijms-20-00372"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abubakar</surname><given-names>I.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name></person-group><article-title>A review on ethnobotany, pharmacology and phytochemistry of Tabernaemontana corymbosa</article-title><source>J. Pharm. Pharmacol.</source><year>2016</year><volume>68</volume><fpage>423</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1111/jphp.12523</pub-id><pub-id pub-id-type="pmid">26887962</pub-id></element-citation></ref><ref id="B10-ijms-20-00372"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasol</surname><given-names>N.E.</given-names></name><name><surname>Ahmad</surname><given-names>F.B.</given-names></name><name><surname>Lim</surname><given-names>X.Y.</given-names></name><name><surname>Chung</surname><given-names>F.F.L.</given-names></name><name><surname>Leong</surname><given-names>C.O.</given-names></name><name><surname>Mai</surname><given-names>C.W.</given-names></name><name><surname>Bihud</surname><given-names>N.V.</given-names></name><name><surname>Zaki</surname><given-names>H.M.</given-names></name><name><surname>Ismail</surname><given-names>N.H.</given-names></name></person-group><article-title>Cytotoxic lactam and naphthoquinone alkaloids from roots of Goniothalamus lanceolatus Miq</article-title><source>Phytochem. Lett.</source><year>2018</year><volume>24</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.phytol.2018.01.009</pub-id></element-citation></ref><ref id="B11-ijms-20-00372"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>V.A.</given-names></name><name><surname>Qazzaz</surname><given-names>M.E.</given-names></name><name><surname>Raja</surname><given-names>V.J.</given-names></name><name><surname>Bradshaw</surname><given-names>T.D.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name><name><surname>Sim</surname><given-names>K.S.</given-names></name><name><surname>Yong</surname><given-names>K.T.</given-names></name><name><surname>Low</surname><given-names>Y.Y.</given-names></name><name><surname>Lim</surname><given-names>K.H.</given-names></name></person-group><article-title>Fistulopsines A and B antiproliferative septicine-type alkaloids from Ficus fistulosa</article-title><source>Phytochem. Lett.</source><year>2016</year><volume>15</volume><fpage>136</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.phytol.2015.12.007</pub-id></element-citation></ref><ref id="B12-ijms-20-00372"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>F.F.</given-names></name><name><surname>Tan</surname><given-names>P.F.</given-names></name><name><surname>Raja</surname><given-names>V.J.</given-names></name><name><surname>Tan</surname><given-names>B.S.</given-names></name><name><surname>Lim</surname><given-names>K.H.</given-names></name><name><surname>Kam</surname><given-names>T.S.</given-names></name><name><surname>Hii</surname><given-names>L.W.</given-names></name><name><surname>Tan</surname><given-names>S.H.</given-names></name><name><surname>See</surname><given-names>S.J.</given-names></name><name><surname>Tan</surname><given-names>Y.F.</given-names></name><etal/></person-group><article-title>Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><pub-id pub-id-type="doi">10.1038/srep42504</pub-id></element-citation></ref><ref id="B13-ijms-20-00372"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Silva</surname><given-names>L.</given-names></name><name><surname>Chuah</surname><given-names>L.H.</given-names></name><name><surname>Meganathan</surname><given-names>P.</given-names></name><name><surname>Fu</surname><given-names>J.Y.</given-names></name></person-group><article-title>Tocotrienol and cancer metastasis</article-title><source>Biofactors</source><year>2016</year><volume>42</volume><fpage>149</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1002/biof.1259</pub-id><?supplied-pmid 26948691?><pub-id pub-id-type="pmid">26948691</pub-id></element-citation></ref><ref id="B14-ijms-20-00372"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazawa</surname><given-names>T.</given-names></name><name><surname>Shibata</surname><given-names>A.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Tsuzuki</surname><given-names>T.</given-names></name></person-group><article-title>Anti-angiogenic function of tocotrienol</article-title><source>Asia Pac. J. Clin. Nutr.</source><year>2008</year><volume>17</volume><fpage>253</fpage><lpage>256</lpage><?supplied-pmid 18296349?><pub-id pub-id-type="pmid">18296349</pub-id></element-citation></ref><ref id="B15-ijms-20-00372"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sailo</surname><given-names>B.L.</given-names></name><name><surname>Banik</surname><given-names>K.</given-names></name><name><surname>Padmavathi</surname><given-names>G.</given-names></name><name><surname>Javadi</surname><given-names>M.</given-names></name><name><surname>Bordoloi</surname><given-names>D.</given-names></name><name><surname>Kunnumakkara</surname><given-names>A.B.</given-names></name></person-group><article-title>Tocotrienols: The promising analogues of vitamin E for cancer therapeutics</article-title><source>Pharmacol. Res.</source><year>2018</year><volume>130</volume><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.02.017</pub-id><?supplied-pmid 29496592?><pub-id pub-id-type="pmid">29496592</pub-id></element-citation></ref><ref id="B16-ijms-20-00372"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>M.I.</given-names></name><name><surname>Adnan</surname><given-names>M.</given-names></name><name><surname>Rahman</surname><given-names>M.M.</given-names></name></person-group><article-title>Natural sources of tocotrienols: A note on absorption</article-title><source>J. Silico Vitr. Pharmacol.</source><year>2017</year><volume>3</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.21767/2469-6692.100020</pub-id></element-citation></ref><ref id="B17-ijms-20-00372"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>P.N.</given-names></name><name><surname>Yap</surname><given-names>W.N.</given-names></name><name><surname>Lee</surname><given-names>D.T.</given-names></name><name><surname>Ling</surname><given-names>M.T.</given-names></name><name><surname>Wong</surname><given-names>Y.C.</given-names></name><name><surname>Yap</surname><given-names>Y.L.</given-names></name></person-group><article-title>Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells</article-title><source>Nutr. Cancer</source><year>2009</year><volume>61</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1080/01635580802567166</pub-id><?supplied-pmid 19373609?><pub-id pub-id-type="pmid">19373609</pub-id></element-citation></ref><ref id="B18-ijms-20-00372"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussein</surname><given-names>D.</given-names></name><name><surname>Mo</surname><given-names>H.</given-names></name></person-group><article-title>&#x003b4;-Tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells</article-title><source>Pancreas</source><year>2009</year><volume>38</volume><fpage>e124</fpage><lpage>e136</lpage><pub-id pub-id-type="doi">10.1097/MPA.0b013e3181a20f9c</pub-id><?supplied-pmid 19346993?><pub-id pub-id-type="pmid">19346993</pub-id></element-citation></ref><ref id="B19-ijms-20-00372"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>W.N.</given-names></name><name><surname>Chang</surname><given-names>P.N.</given-names></name><name><surname>Han</surname><given-names>H.Y.</given-names></name><name><surname>Lee</surname><given-names>D.T.</given-names></name><name><surname>Ling</surname><given-names>M.T.</given-names></name><name><surname>Wong</surname><given-names>Y.C.</given-names></name><name><surname>Yap</surname><given-names>Y.L.</given-names></name></person-group><article-title>Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways</article-title><source>Br. J. Cancer</source><year>2008</year><volume>99</volume><fpage>1832</fpage><lpage>1841</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604763</pub-id><pub-id pub-id-type="pmid">19002171</pub-id></element-citation></ref><ref id="B20-ijms-20-00372"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abubakar</surname><given-names>I.B.</given-names></name><name><surname>Lim</surname><given-names>K.H.</given-names></name><name><surname>Kam</surname><given-names>T.S.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name></person-group><article-title>Enhancement of apoptotic activities on brain cancer cells via the combination of &#x003b3;-tocotrienol and jerantinine A</article-title><source>Phytomedicine</source><year>2017</year><volume>30</volume><fpage>74</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2017.03.004</pub-id><pub-id pub-id-type="pmid">28545672</pub-id></element-citation></ref><ref id="B21-ijms-20-00372"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>M.K.</given-names></name><name><surname>Agarwal</surname><given-names>M.L.</given-names></name><name><surname>Athar</surname><given-names>M.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association</article-title><source>Cell Cycle</source><year>2004</year><volume>13</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.4161/cc.3.2.637</pub-id></element-citation></ref><ref id="B22-ijms-20-00372"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>J.K.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2006</year><volume>346</volume><fpage>447</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.05.147</pub-id><?supplied-pmid 16762318?><pub-id pub-id-type="pmid">16762318</pub-id></element-citation></ref><ref id="B23-ijms-20-00372"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.S.</given-names></name><name><surname>Zhang</surname><given-names>S.J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>Y.H.</given-names></name><name><surname>He</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>P.H.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Guan</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>J.R.</given-names></name></person-group><article-title>Tocotrienol-rich fraction (TRF) suppresses the growth of human colon cancer xenografts in Balb/C nude mice by the Wnt pathway</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0122175</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0122175</pub-id><?supplied-pmid 25807493?><pub-id pub-id-type="pmid">25807493</pub-id></element-citation></ref><ref id="B24-ijms-20-00372"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zugazagoitia</surname><given-names>J.</given-names></name><name><surname>Guedes</surname><given-names>C.</given-names></name><name><surname>Ponce</surname><given-names>S.</given-names></name><name><surname>Ferrer</surname><given-names>I.</given-names></name><name><surname>Molina-Pinelo</surname><given-names>S.</given-names></name><name><surname>Paz-Ares</surname><given-names>L.</given-names></name></person-group><article-title>Current challenges in cancer treatment</article-title><source>Clin. Ther.</source><year>2016</year><volume>38</volume><fpage>1551</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2016.03.026</pub-id><pub-id pub-id-type="pmid">27158009</pub-id></element-citation></ref><ref id="B25-ijms-20-00372"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Palma</surname><given-names>M.</given-names></name><name><surname>Hanahan</surname><given-names>D.</given-names></name></person-group><article-title>The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities</article-title><source>Mol. Oncol.</source><year>2012</year><volume>6</volume><fpage>111</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2012.01.011</pub-id><pub-id pub-id-type="pmid">22360993</pub-id></element-citation></ref><ref id="B26-ijms-20-00372"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labi</surname><given-names>V.</given-names></name><name><surname>Erlacher</surname><given-names>M.</given-names></name></person-group><article-title>How cell death shapes cancer</article-title><source>Cell Death Dis.</source><year>2015</year><volume>6</volume><pub-id pub-id-type="doi">10.1038/cddis.2015.20</pub-id><?supplied-pmid 25741600?><pub-id pub-id-type="pmid">25741600</pub-id></element-citation></ref><ref id="B27-ijms-20-00372"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meganathan</surname><given-names>P.</given-names></name><name><surname>Fu</surname><given-names>J.Y.</given-names></name></person-group><article-title>Biological properties of tocotrienols: Evidence in human dtudies</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>1682</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17111682</pub-id><?supplied-pmid 27792171?><pub-id pub-id-type="pmid">27792171</pub-id></element-citation></ref><ref id="B28-ijms-20-00372"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>K.Y.</given-names></name><name><surname>Pang</surname><given-names>K.L.</given-names></name><name><surname>Soelaiman</surname><given-names>I.N.</given-names></name></person-group><article-title>Tocotrienol and its role in chronic diseases</article-title><source>Anti-Inflammatory Nutraceuticals and Chronic Diseases</source><person-group person-group-type="editor"><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Aggarwal</surname><given-names>B.</given-names></name></person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2016</year><volume>Volume 928</volume><fpage>97</fpage><lpage>130</lpage></element-citation></ref><ref id="B29-ijms-20-00372"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahsan</surname><given-names>H.</given-names></name><name><surname>Ahad</surname><given-names>A.</given-names></name><name><surname>Iqbal</surname><given-names>J.</given-names></name><name><surname>Siddiqui</surname><given-names>W.A.</given-names></name></person-group><article-title>Pharmacological potential of tocotrienols: A review</article-title><source>Nutr. Metab.</source><year>2014</year><volume>11</volume><pub-id pub-id-type="doi">10.1186/1743-7075-11-52</pub-id><?supplied-pmid 25435896?><pub-id pub-id-type="pmid">25435896</pub-id></element-citation></ref><ref id="B30-ijms-20-00372"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>Y.</given-names></name><name><surname>Steller</surname><given-names>H.</given-names></name></person-group><article-title>Programmed cell death in animal development and disease</article-title><source>Cell</source><year>2011</year><volume>147</volume><fpage>742</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.10.033</pub-id><?supplied-pmid 22078876?><pub-id pub-id-type="pmid">22078876</pub-id></element-citation></ref><ref id="B31-ijms-20-00372"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S.</given-names></name></person-group><article-title>Regulation of cell death in cancer-possible implications for immunotherapy</article-title><source>Front. Oncol.</source><year>2013</year><volume>3</volume><pub-id pub-id-type="doi">10.3389/fonc.2013.00029</pub-id></element-citation></ref><ref id="B32-ijms-20-00372"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantari</surname><given-names>C.</given-names></name><name><surname>Walczak</surname><given-names>H.</given-names></name></person-group><article-title>Caspase-8 and Bid: Caught in the act between death receptors and mitochondria</article-title><source>Biochim. Biophys. Acta Mol. Cell Res.</source><year>2011</year><volume>1813</volume><fpage>558</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.01.026</pub-id></element-citation></ref><ref id="B33-ijms-20-00372"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>R.S.Y.</given-names></name></person-group><article-title>Apoptosis in cancer: From pathogenesis to treatment</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2011</year><volume>30</volume><pub-id pub-id-type="doi">10.1186/1756-9966-30-87</pub-id></element-citation></ref><ref id="B34-ijms-20-00372"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalkavan</surname><given-names>H.</given-names></name><name><surname>Green</surname><given-names>D.R.</given-names></name></person-group><article-title>MOMP, cell suicide as a BCL-2 family business</article-title><source>Cell Death Differ.</source><year>2018</year><volume>25</volume><fpage>46</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.179</pub-id><?supplied-pmid 29053143?><pub-id pub-id-type="pmid">29053143</pub-id></element-citation></ref><ref id="B35-ijms-20-00372"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>M.H.</given-names></name><name><surname>Thompson</surname><given-names>C.B.</given-names></name></person-group><article-title>The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability</article-title><source>Cell Death Differ.</source><year>2000</year><volume>7</volume><fpage>1182</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400781</pub-id><pub-id pub-id-type="pmid">11175255</pub-id></element-citation></ref><ref id="B36-ijms-20-00372"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brentnall</surname><given-names>M.</given-names></name><name><surname>Rodriguez-Menocal</surname><given-names>L.</given-names></name><name><surname>De Guevara</surname><given-names>R.L.</given-names></name><name><surname>Cepero</surname><given-names>E.</given-names></name><name><surname>Boise</surname><given-names>L.H.</given-names></name></person-group><article-title>Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis</article-title><source>BMC Cell Biol.</source><year>2013</year><volume>14</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2121-14-32</pub-id><?supplied-pmid 23834359?><pub-id pub-id-type="pmid">23834359</pub-id></element-citation></ref><ref id="B37-ijms-20-00372"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glick</surname><given-names>D.</given-names></name><name><surname>Barth</surname><given-names>S.</given-names></name><name><surname>Macleod</surname><given-names>K.F.</given-names></name></person-group><article-title>Autophagy: Cellular and molecular mechanisms</article-title><source>J. Pathol.</source><year>2010</year><volume>221</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1002/path.2697</pub-id><?supplied-pmid 20225336?><pub-id pub-id-type="pmid">20225336</pub-id></element-citation></ref><ref id="B38-ijms-20-00372"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nesaretnam</surname><given-names>K.S.</given-names></name><name><surname>Kanga</surname><given-names>R.</given-names></name><name><surname>Abdul-Razak</surname><given-names>G.</given-names></name><name><surname>Veerasenan</surname><given-names>S.D.</given-names></name><name><surname>Gomez</surname><given-names>P.A.</given-names></name></person-group><article-title>Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: A pilot clinical trial</article-title><source>Breast Cancer Res.</source><year>2010</year><volume>12</volume><pub-id pub-id-type="doi">10.1186/bcr2726</pub-id></element-citation></ref><ref id="B39-ijms-20-00372"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parajuli</surname><given-names>P.</given-names></name><name><surname>Tiwari</surname><given-names>R.V.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name></person-group><article-title>Anti-proliferative effects of gamma-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells</article-title><source>Cell Prolif.</source><year>2015</year><volume>48</volume><fpage>421</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1111/cpr.12196</pub-id><pub-id pub-id-type="pmid">26096843</pub-id></element-citation></ref><ref id="B40-ijms-20-00372"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S.W.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name><name><surname>Ting</surname><given-names>K.N.</given-names></name><name><surname>Bradshaw</surname><given-names>T.D.</given-names></name><name><surname>Zeenathul</surname><given-names>N.A.</given-names></name></person-group><article-title>Cytotoxicity and apoptotic activities of alpha-, gamma- and delta-tocotrienol isomers on human cancer cells</article-title><source>BMC Complement. Altern. Med.</source><year>2014</year><volume>14</volume><elocation-id>469</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6882-14-469</pub-id><pub-id pub-id-type="pmid">25480449</pub-id></element-citation></ref><ref id="B41-ijms-20-00372"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abubakar</surname><given-names>I.B.</given-names></name><name><surname>Lim</surname><given-names>K.H.</given-names></name><name><surname>Kam</surname><given-names>T.S.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name></person-group><article-title>Synergistic cytotoxic effects of combined &#x003b4;-tocotrienol and jerantinine B on human brain and colon cancers</article-title><source>J. Ethnopharmacol.</source><year>2016</year><volume>184</volume><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2016.03.004</pub-id><pub-id pub-id-type="pmid">26947901</pub-id></element-citation></ref><ref id="B42-ijms-20-00372"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Du</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol inhibits cell viability through suppression of &#x003b2;-catenin/Tcf signaling in human colon carcinoma HT-29 cells</article-title><source>J. Nutr. Biochem.</source><year>2012</year><volume>23</volume><fpage>800</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2011.04.003</pub-id><pub-id pub-id-type="pmid">21852086</pub-id></element-citation></ref><ref id="B43-ijms-20-00372"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abubakar</surname><given-names>I.B.</given-names></name><name><surname>Lim</surname><given-names>K.H.</given-names></name><name><surname>Kam</surname><given-names>T.S.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name></person-group><article-title>Jerantinine B enhances the mitochondria-mediated apoptosis by p53 Activation in human glioblastoma cells via a combination with &#x003b4;-tocotrienol</article-title><source>J. Biol. Act. Prod. Nat.</source><year>2018</year><volume>8</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1080/22311866.2018.1440253</pub-id></element-citation></ref><ref id="B44-ijms-20-00372"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burdeos</surname><given-names>G.C.</given-names></name><name><surname>Ito</surname><given-names>J.</given-names></name><name><surname>Eitsuka</surname><given-names>T.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Kimura</surname><given-names>F.</given-names></name><name><surname>Miyazawa</surname><given-names>T.</given-names></name></person-group><article-title>&#x003b4; and &#x003b3; tocotrienols suppress human hepatocellular carcinoma cell proliferation via regulation of Ras-Raf-MEK-ERK pathway-associated upstream signaling</article-title><source>Food Funct.</source><year>2016</year><volume>7</volume><fpage>4170</fpage><lpage>4174</lpage><pub-id pub-id-type="doi">10.1039/C6FO00826G</pub-id><pub-id pub-id-type="pmid">27713963</pub-id></element-citation></ref><ref id="B45-ijms-20-00372"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname><given-names>M.</given-names></name><name><surname>Okabe</surname><given-names>M.</given-names></name><name><surname>Tachibana</surname><given-names>H.</given-names></name><name><surname>Yamada</surname><given-names>K.</given-names></name></person-group><article-title>Apoptosis induction by gamma-tocotrienol in human hepatoma Hep3B cells</article-title><source>J. Nutr. Biochem.</source><year>2006</year><volume>17</volume><fpage>672</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2005.11.001</pub-id><pub-id pub-id-type="pmid">16517139</pub-id></element-citation></ref><ref id="B46-ijms-20-00372"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Mi</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>P.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name><name><surname>Niu</surname><given-names>L.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol inhibits proliferation and induces apoptosis via the mitochondrial pathway in human cancer HeLa cells</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1299</elocation-id></element-citation></ref><ref id="B47-ijms-20-00372"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>M.</given-names></name><name><surname>Nishimura</surname><given-names>M.</given-names></name><name><surname>Sakakibara</surname><given-names>Y.</given-names></name><name><surname>Suiko</surname><given-names>M.</given-names></name><name><surname>Morishita</surname><given-names>K.</given-names></name><name><surname>Nishiyama</surname><given-names>K.</given-names></name></person-group><article-title>Delta-tocotrienol induces apoptotic cell death via depletion of intracellular squalene in ED40515 cells</article-title><source>Food Funct.</source><year>2014</year><volume>5</volume><fpage>2842</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1039/C4FO00635F</pub-id><?supplied-pmid 25225850?><pub-id pub-id-type="pmid">25225850</pub-id></element-citation></ref><ref id="B48-ijms-20-00372"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>N.V.</given-names></name><name><surname>Guntipalli</surname><given-names>P.K.</given-names></name><name><surname>Mo</surname><given-names>H.</given-names></name></person-group><article-title>&#x003b4;-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells</article-title><source>Anticancer Res.</source><year>2010</year><volume>30</volume><fpage>4937</fpage><lpage>4944</lpage><pub-id pub-id-type="pmid">21187473</pub-id></element-citation></ref><ref id="B49-ijms-20-00372"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S.</given-names></name><name><surname>Galluzzi</surname><given-names>L.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Targeting mitochondria for cancer therapy</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>447</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/nrd3137</pub-id><?supplied-pmid 20467424?><pub-id pub-id-type="pmid">20467424</pub-id></element-citation></ref><ref id="B50-ijms-20-00372"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Loo</surname><given-names>G.</given-names></name></person-group><article-title>Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells</article-title><source>Biochem. Pharmacol.</source><year>2004</year><volume>67</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2003.07.015</pub-id><?supplied-pmid 14698044?><pub-id pub-id-type="pmid">14698044</pub-id></element-citation></ref><ref id="B51-ijms-20-00372"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>A.</given-names></name><name><surname>Takitani</surname><given-names>K.</given-names></name><name><surname>Koh</surname><given-names>M.</given-names></name><name><surname>Kawakami</surname><given-names>C.</given-names></name><name><surname>Kuno</surname><given-names>T.</given-names></name><name><surname>Tamai</surname><given-names>H.</given-names></name></person-group><article-title>Induction of apoptosis by &#x003b3;-tocotrienol in human cancer cell lines and leukemic blasts from patients: Dependency on Bid, cytochrome c, and caspase pathway</article-title><source>Nutr. Cancer</source><year>2011</year><volume>63</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1080/01635581.2011.563030</pub-id><pub-id pub-id-type="pmid">21660856</pub-id></element-citation></ref><ref id="B52-ijms-20-00372"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abubakar</surname><given-names>I.B.</given-names></name><name><surname>Lim</surname><given-names>K.H.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name></person-group><article-title>Alkaloid extracts of Ficus species and palm oil-derived tocotrienols synergistically inhibit proliferation of human cancer cells</article-title><source>Nat. Prod. Res.</source><year>2014</year><volume>29</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">25204784</pub-id></element-citation></ref><ref id="B53-ijms-20-00372"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickmann</surname><given-names>M.</given-names></name><name><surname>Vaquero</surname><given-names>E.C.</given-names></name><name><surname>Malagelada</surname><given-names>J.R.</given-names></name><name><surname>Molero</surname><given-names>X.</given-names></name></person-group><article-title>Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><fpage>2518</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2007.03.107</pub-id><?supplied-pmid 17570223?><pub-id pub-id-type="pmid">17570223</pub-id></element-citation></ref><ref id="B54-ijms-20-00372"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komar</surname><given-names>H.M.</given-names></name><name><surname>Serpa</surname><given-names>G.</given-names></name><name><surname>Kerscher</surname><given-names>C.</given-names></name><name><surname>Schwoegl</surname><given-names>E.</given-names></name><name><surname>Mace</surname><given-names>T.A.</given-names></name><name><surname>Jin</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>M.C.</given-names></name><name><surname>Chen</surname><given-names>C.S.</given-names></name><name><surname>Bloomston</surname><given-names>M.</given-names></name><name><surname>Ostrowski</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-01973-0</pub-id><?supplied-pmid 28496202?><pub-id pub-id-type="pmid">28127051</pub-id></element-citation></ref><ref id="B55-ijms-20-00372"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajendran</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Manu</surname><given-names>K.A.</given-names></name><name><surname>Shanmugam</surname><given-names>M.K.</given-names></name><name><surname>Loo</surname><given-names>S.Y.</given-names></name><name><surname>Kumar</surname><given-names>A.P.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: Potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent</article-title><source>Br. J. Pharmacol.</source><year>2011</year><volume>163</volume><fpage>283</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01187.x</pub-id><?supplied-pmid 21198544?><pub-id pub-id-type="pmid">21198544</pub-id></element-citation></ref><ref id="B56-ijms-20-00372"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W.L.</given-names></name><name><surname>Liu</surname><given-names>J.R.</given-names></name><name><surname>Liu</surname><given-names>H.K.</given-names></name><name><surname>Qi</surname><given-names>G.Y.</given-names></name><name><surname>Sun</surname><given-names>X.R.</given-names></name><name><surname>Sun</surname><given-names>W.G.</given-names></name><name><surname>Chen</surname><given-names>B.Q.</given-names></name></person-group><article-title>Inhibition of proliferation and induction of apoptosis by gamma-tocotrienol in human colon carcinoma HT-29 cells</article-title><source>Nutrition</source><year>2009</year><volume>25</volume><fpage>555</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2008.10.019</pub-id><?supplied-pmid 19121919?><pub-id pub-id-type="pmid">19121919</pub-id></element-citation></ref><ref id="B57-ijms-20-00372"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J.K.</given-names></name><name><surname>Then</surname><given-names>S.M.</given-names></name><name><surname>Mazlan</surname><given-names>M.</given-names></name><name><surname>Raja Abdul Rahman</surname><given-names>R.N.</given-names></name><name><surname>Jamal</surname><given-names>R.</given-names></name><name><surname>Wan Ngah</surname><given-names>W.Z.</given-names></name></person-group><article-title>Gamma-tocotrienol acts as a BH3 mimetic to induce apoptosis in neuroblastoma SH-SY5Y cells</article-title><source>J. Nutr. Biochem.</source><year>2016</year><volume>31</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2015.12.019</pub-id><pub-id pub-id-type="pmid">27133421</pub-id></element-citation></ref><ref id="B58-ijms-20-00372"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Husain</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Centeno</surname><given-names>B.A.</given-names></name><name><surname>Chen</surname><given-names>D.T.</given-names></name><name><surname>Tong</surname><given-names>Z.</given-names></name><name><surname>Sebti</surname><given-names>S.M.</given-names></name><name><surname>Malafa</surname><given-names>M.P.</given-names></name></person-group><article-title>EGR-1/Bax pathway plays a role in vitamin E &#x003b4;-tocotrienol-induced apoptosis in pancreatic cancer cells</article-title><source>J. Nutr. Biochem.</source><year>2015</year><volume>26</volume><fpage>797</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2015.02.008</pub-id><pub-id pub-id-type="pmid">25997867</pub-id></element-citation></ref><ref id="B59-ijms-20-00372"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>S.C.</given-names></name><name><surname>Tyagi</surname><given-names>A.K.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules</article-title><source>Br. J. Cancer</source><year>2016</year><volume>115</volume><fpage>814</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.257</pub-id><pub-id pub-id-type="pmid">27575851</pub-id></element-citation></ref><ref id="B60-ijms-20-00372"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kannappan</surname><given-names>R.</given-names></name><name><surname>Ravindran</surname><given-names>J.</given-names></name><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Yadav</surname><given-names>V.R.</given-names></name><name><surname>Reuter</surname><given-names>S.</given-names></name><name><surname>Chaturvedi</surname><given-names>M.M.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors</article-title><source>Mol. Cancer Ther.</source><year>2010</year><volume>9</volume><fpage>2196</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-0277</pub-id><?supplied-pmid 20682650?><pub-id pub-id-type="pmid">20682650</pub-id></element-citation></ref><ref id="B61-ijms-20-00372"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilankar</surname><given-names>C.</given-names></name><name><surname>Khan</surname><given-names>N.M.</given-names></name><name><surname>Checker</surname><given-names>R.</given-names></name><name><surname>Sharma</surname><given-names>D.</given-names></name><name><surname>Patwardhan</surname><given-names>R.</given-names></name><name><surname>Gota</surname><given-names>V.</given-names></name><name><surname>Sandur</surname><given-names>S.K.</given-names></name><name><surname>Devasagayam</surname><given-names>T.P.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol induces apoptosis in human T cell lymphoma through activation of both intrinsic and extrinsic pathways</article-title><source>Curr. Pharm. Des.</source><year>2011</year><volume>17</volume><fpage>2176</fpage><lpage>2189</lpage><pub-id pub-id-type="doi">10.2174/138161211796957463</pub-id><pub-id pub-id-type="pmid">21774779</pub-id></element-citation></ref><ref id="B62-ijms-20-00372"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senft</surname><given-names>D.</given-names></name><name><surname>Ronai</surname><given-names>Z.A.</given-names></name></person-group><article-title>UPR, autophagy, and mitochondria crosstalk underlies the ER stress response</article-title><source>Trends Biochem. Sci.</source><year>2015</year><volume>40</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2015.01.002</pub-id><pub-id pub-id-type="pmid">25656104</pub-id></element-citation></ref><ref id="B63-ijms-20-00372"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avril</surname><given-names>T.</given-names></name><name><surname>Vaul&#x000e9;on</surname><given-names>E.</given-names></name><name><surname>Chevet</surname><given-names>E.</given-names></name></person-group><article-title>Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers</article-title><source>Oncogenesis</source><year>2017</year><volume>6</volume><pub-id pub-id-type="doi">10.1038/oncsis.2017.72</pub-id><?supplied-pmid 28846078?><pub-id pub-id-type="pmid">28846078</pub-id></element-citation></ref><ref id="B64-ijms-20-00372"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>R.</given-names></name><name><surname>Reed</surname><given-names>J.C.</given-names></name></person-group><article-title>ER stress-induced cell death mechanisms</article-title><source>Biochim. Biophys. Acta Mol. Cell Res.</source><year>2013</year><volume>1833</volume><fpage>3460</fpage><lpage>3470</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.06.028</pub-id><?supplied-pmid 23850759?><pub-id pub-id-type="pmid">23850759</pub-id></element-citation></ref><ref id="B65-ijms-20-00372"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>E.</given-names></name><name><surname>Chiaradia</surname><given-names>D.C.</given-names></name><name><surname>Silva</surname><given-names>A.H.</given-names></name><name><surname>Nunes</surname><given-names>R.J.</given-names></name><name><surname>Yunes</surname><given-names>R.A.</given-names></name><name><surname>Creczynski-Pasa</surname><given-names>T.B.</given-names></name></person-group><article-title>Involvement of extrinsic and intrinsic apoptotic pathways together with endoplasmic reticulum stress in cell death induced by naphthylchalcones in a leukemic cell line: Advantages of multi-target action</article-title><source>Toxicol. Vitro</source><year>2014</year><volume>28</volume><fpage>769</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2014.02.002</pub-id><?supplied-pmid 24583196?><pub-id pub-id-type="pmid">24583196</pub-id></element-citation></ref><ref id="B66-ijms-20-00372"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krajarng</surname><given-names>A.</given-names></name><name><surname>Imoto</surname><given-names>M.</given-names></name><name><surname>Tashiro</surname><given-names>E.</given-names></name><name><surname>Fujimaki</surname><given-names>T.</given-names></name><name><surname>Shinjo</surname><given-names>S.</given-names></name><name><surname>Watanapokasin</surname><given-names>R.</given-names></name></person-group><article-title>Apoptosis induction associated with the ER stress response through up-regulation of JNK in HeLa cells by gambogic acid</article-title><source>BMC Complement. Altern. Med.</source><year>2015</year><volume>15</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-015-0544-4</pub-id><pub-id pub-id-type="pmid">25887496</pub-id></element-citation></ref><ref id="B67-ijms-20-00372"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Miao</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name></person-group><article-title>Activation of endoplasmic reticulum stress and the extrinsic apoptotic pathway in human lung cancer cells by the new synthetic flavonoid, LZ-205</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>87257</fpage><lpage>87270</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.13535</pub-id><pub-id pub-id-type="pmid">27895312</pub-id></element-citation></ref><ref id="B68-ijms-20-00372"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wali</surname><given-names>V.B.</given-names></name><name><surname>Bachawal</surname><given-names>S.V.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name></person-group><article-title>Endoplasmic reticulum stress mediates gamma-tocotrienol-induced apoptosis in mammary tumor cells</article-title><source>Apoptosis</source><year>2009</year><volume>14</volume><fpage>1366</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1007/s10495-009-0406-y</pub-id><?supplied-pmid 19771520?><pub-id pub-id-type="pmid">19771520</pub-id></element-citation></ref><ref id="B69-ijms-20-00372"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patacsil</surname><given-names>D.</given-names></name><name><surname>Tran</surname><given-names>A.T.</given-names></name><name><surname>Cho</surname><given-names>Y.S.</given-names></name><name><surname>Suy</surname><given-names>S.</given-names></name><name><surname>Saenz</surname><given-names>F.</given-names></name><name><surname>Malyukova</surname><given-names>I.</given-names></name><name><surname>Ressom</surname><given-names>H.</given-names></name><name><surname>Collins</surname><given-names>S.P.</given-names></name><name><surname>Clarke</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>D.</given-names></name></person-group><article-title>Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells</article-title><source>J. Nutr. Biochem.</source><year>2012</year><volume>23</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2010.11.012</pub-id><pub-id pub-id-type="pmid">21429729</pub-id></element-citation></ref><ref id="B70-ijms-20-00372"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comitato</surname><given-names>R.</given-names></name><name><surname>Guantario</surname><given-names>R.</given-names></name><name><surname>Leoni</surname><given-names>G.</given-names></name><name><surname>Nesaretnam</surname><given-names>K.</given-names></name><name><surname>Ronci</surname><given-names>M.B.</given-names></name><name><surname>Canali</surname><given-names>R.</given-names></name><name><surname>Virgili</surname><given-names>F.</given-names></name></person-group><article-title>Tocotrienols induce endoplasmic reticulum stress and apoptosis in cervical cancer cells</article-title><source>Genes Nutr.</source><year>2016</year><volume>11</volume><pub-id pub-id-type="doi">10.1186/s12263-016-0543-1</pub-id></element-citation></ref><ref id="B71-ijms-20-00372"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagnani</surname><given-names>M.M.</given-names></name><name><surname>Marzagalli</surname><given-names>M.</given-names></name><name><surname>Moretti</surname><given-names>R.M.</given-names></name><name><surname>Beretta</surname><given-names>G.</given-names></name><name><surname>Casati</surname><given-names>L.</given-names></name><name><surname>Comitato</surname><given-names>R.</given-names></name><name><surname>Gravina</surname><given-names>G.L.</given-names></name><name><surname>Festuccia</surname><given-names>C.</given-names></name><name><surname>Limonta</surname><given-names>P.</given-names></name></person-group><article-title>Vitamin E &#x003b4;-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><pub-id pub-id-type="doi">10.1038/srep30502</pub-id></element-citation></ref><ref id="B72-ijms-20-00372"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dadey</surname><given-names>D.Y.</given-names></name><name><surname>Kapoor</surname><given-names>V.</given-names></name><name><surname>Khudanyan</surname><given-names>A.</given-names></name><name><surname>Urano</surname><given-names>F.</given-names></name><name><surname>Kim</surname><given-names>A.H.</given-names></name><name><surname>Thotala</surname><given-names>D.</given-names></name><name><surname>Hallahan</surname><given-names>D.E.</given-names></name></person-group><article-title>The ATF6 pathway of the ER stress response contributes to enhanced viability in glioblastoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>2080</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6712</pub-id><pub-id pub-id-type="pmid">26716508</pub-id></element-citation></ref><ref id="B73-ijms-20-00372"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S.K.</given-names></name><name><surname>Sanders</surname><given-names>B.G.</given-names></name><name><surname>Kline</surname><given-names>K.</given-names></name></person-group><article-title>Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling</article-title><source>Breast Cancer Res. Treat.</source><year>2010</year><volume>124</volume><fpage>361</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1007/s10549-010-0786-2</pub-id><?supplied-pmid 20157774?><pub-id pub-id-type="pmid">20157774</pub-id></element-citation></ref><ref id="B74-ijms-20-00372"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchi</surname><given-names>S.</given-names></name><name><surname>Patergnani</surname><given-names>S.</given-names></name><name><surname>Pinton</surname><given-names>P.</given-names></name></person-group><article-title>The endoplasmic reticulum&#x02013;mitochondria connection: One touch, multiple functions</article-title><source>Biochim. Biophys. Acta Bioenerg.</source><year>2014</year><volume>1837</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2013.10.015</pub-id></element-citation></ref><ref id="B75-ijms-20-00372"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iurlaro</surname><given-names>R.</given-names></name><name><surname>Mu&#x000f1;oz-Pinedo</surname><given-names>C.</given-names></name></person-group><article-title>Cell death induced by endoplasmic reticulum stress</article-title><source>FEBS J.</source><year>2016</year><volume>283</volume><fpage>2640</fpage><lpage>2652</lpage><pub-id pub-id-type="doi">10.1111/febs.13598</pub-id><?supplied-pmid 26587781?><pub-id pub-id-type="pmid">26587781</pub-id></element-citation></ref><ref id="B76-ijms-20-00372"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bustos</surname><given-names>G.</given-names></name><name><surname>Cruz</surname><given-names>P.</given-names></name><name><surname>Lovy</surname><given-names>A.</given-names></name><name><surname>C&#x000e1;rdenas</surname><given-names>C.</given-names></name></person-group><article-title>Endoplasmic reticulum&#x02013;mitochondria calcium communication and the regulation of mitochondrial metabolism in cancer: A novel potential target</article-title><source>Front. Oncol.</source><year>2017</year><fpage>7</fpage><pub-id pub-id-type="doi">10.3389/fonc.2017.00199</pub-id><pub-id pub-id-type="pmid">28168165</pub-id></element-citation></ref><ref id="B77-ijms-20-00372"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>D.</given-names></name><name><surname>Rojas-Rivera</surname><given-names>D.</given-names></name><name><surname>Hetz</surname><given-names>C.</given-names></name></person-group><article-title>Integrating stress signals at the endoplasmic reticulum: The BCL-2 protein family rheostat</article-title><source>Biochim. Biophys. Acta Mol. Cell Res.</source><year>2011</year><volume>1813</volume><fpage>564</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2010.11.012</pub-id><?supplied-pmid 21122809?><pub-id pub-id-type="pmid">21122809</pub-id></element-citation></ref><ref id="B78-ijms-20-00372"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galehdar</surname><given-names>Z.</given-names></name><name><surname>Swan</surname><given-names>P.</given-names></name><name><surname>Fuerth</surname><given-names>B.</given-names></name><name><surname>Callaghan</surname><given-names>S.M.</given-names></name><name><surname>Park</surname><given-names>D.S.</given-names></name><name><surname>Cregan</surname><given-names>S.P.</given-names></name></person-group><article-title>Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA</article-title><source>J. Neurosci.</source><year>2010</year><volume>30</volume><fpage>16938</fpage><lpage>16948</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1598-10.2010</pub-id><?supplied-pmid 21159964?><pub-id pub-id-type="pmid">21159964</pub-id></element-citation></ref><ref id="B79-ijms-20-00372"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pike</surname><given-names>L.R.G.</given-names></name><name><surname>Phadwal</surname><given-names>K.</given-names></name><name><surname>Simon</surname><given-names>A.K.</given-names></name><name><surname>Harris</surname><given-names>A.L.</given-names></name></person-group><article-title>ATF4 orchestrates a program of BH3-only protein expression in severe hypoxia</article-title><source>Mol. Biol. Rep.</source><year>2012</year><volume>39</volume><fpage>10811</fpage><lpage>10822</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-1975-3</pub-id><pub-id pub-id-type="pmid">23090478</pub-id></element-citation></ref><ref id="B80-ijms-20-00372"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>K.L.</given-names></name><name><surname>Ammu</surname><given-names>K.R.</given-names></name><name><surname>Selvaduray</surname><given-names>K.R.</given-names></name></person-group><article-title>Apoptosis gene network regulated by delta-tocotrienol in K562 chronic myeloid leukemia cells</article-title><source>J. Oil Palm Res.</source><year>2016</year><volume>29</volume><fpage>251</fpage><lpage>261</lpage></element-citation></ref><ref id="B81-ijms-20-00372"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S.</given-names></name><name><surname>Debatin</surname><given-names>K.M.</given-names></name></person-group><article-title>Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>4798</fpage><lpage>4811</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209608</pub-id><pub-id pub-id-type="pmid">16892092</pub-id></element-citation></ref><ref id="B82-ijms-20-00372"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudner</surname><given-names>J.</given-names></name><name><surname>Jendrossek</surname><given-names>V.</given-names></name><name><surname>Lauber</surname><given-names>K.</given-names></name><name><surname>Daniel</surname><given-names>P.T.</given-names></name><name><surname>Wesselborg</surname><given-names>S.</given-names></name><name><surname>Belka</surname><given-names>C.</given-names></name></person-group><article-title>Type I and type II reactions in TRAIL-induced apoptosis&#x02014;Results from dose&#x02013;response studies</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>130</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208191</pub-id><pub-id pub-id-type="pmid">15531922</pub-id></element-citation></ref><ref id="B83-ijms-20-00372"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>A.T.</given-names></name><name><surname>Ramalinga</surname><given-names>M.</given-names></name><name><surname>Kedir</surname><given-names>H.</given-names></name><name><surname>Clarke</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>D.</given-names></name></person-group><article-title>Autophagy inhibitor 3-methyladenine potentiates apoptosis induced by dietary tocotrienols in breast cancer cells</article-title><source>Eur. J. Nutr.</source><year>2015</year><volume>54</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s00394-014-0707-y</pub-id><?supplied-pmid 24830781?><pub-id pub-id-type="pmid">24830781</pub-id></element-citation></ref><ref id="B84-ijms-20-00372"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gump</surname><given-names>J.M.</given-names></name><name><surname>Thorburn</surname><given-names>A.</given-names></name></person-group><article-title>Autophagy and apoptosis: What is the connection?</article-title><source>Trends Cell Biol.</source><year>2011</year><volume>21</volume><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2011.03.007</pub-id><pub-id pub-id-type="pmid">21561772</pub-id></element-citation></ref><ref id="B85-ijms-20-00372"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaquero</surname><given-names>E.C.</given-names></name><name><surname>Rickmann</surname><given-names>M.</given-names></name><name><surname>Molero</surname><given-names>X.</given-names></name></person-group><article-title>Tocotrienols balancing the mitochondrial crosstalk between apoptosis and autophagy tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway</article-title><source>Autophagy</source><year>2007</year><volume>3</volume><fpage>652</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.4161/auto.5088</pub-id><?supplied-pmid 17932465?><pub-id pub-id-type="pmid">17932465</pub-id></element-citation></ref><ref id="B86-ijms-20-00372"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>R.V.</given-names></name><name><surname>Parajuli</surname><given-names>P.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name></person-group><article-title>Synergistic anticancer effects of combined &#x003b3;-tocotrienol and oridonin treatment is associated with the induction of autophagy</article-title><source>Mol. Cell. Biochem.</source><year>2015</year><volume>408</volume><fpage>123</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/s11010-015-2488-x</pub-id><?supplied-pmid 26112904?><pub-id pub-id-type="pmid">26112904</pub-id></element-citation></ref><ref id="B87-ijms-20-00372"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Q.</given-names></name><name><surname>Rao</surname><given-names>X.</given-names></name><name><surname>Kim</surname><given-names>C.Y.</given-names></name><name><surname>Freiser</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group><article-title>Gamma-tocotrienol induces apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and dihydroceramide</article-title><source>Int. J. Cancer</source><year>2012</year><volume>130</volume><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1002/ijc.26054</pub-id><?supplied-pmid 21400505?><pub-id pub-id-type="pmid">21400505</pub-id></element-citation></ref><ref id="B88-ijms-20-00372"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>R.V.</given-names></name><name><surname>Parajuli</surname><given-names>P.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol-induced autophagy in malignant mammary cancer cells</article-title><source>Exp. Biol. Med.</source><year>2013</year><volume>239</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1177/1535370213511022</pub-id><?supplied-pmid 24231340?><pub-id pub-id-type="pmid">24231340</pub-id></element-citation></ref><ref id="B89-ijms-20-00372"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>R.V.</given-names></name><name><surname>Parajuli</surname><given-names>P.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol-induced endoplasmic reticulum stress and autophagy act concurrently to promote breast cancer cell death</article-title><source>Biochem. Cell Biol.</source><year>2015</year><volume>93</volume><fpage>306</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1139/bcb-2014-0123</pub-id><?supplied-pmid 25844964?><pub-id pub-id-type="pmid">25844964</pub-id></element-citation></ref><ref id="B90-ijms-20-00372"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Palma</surname><given-names>C.</given-names></name><name><surname>Perrotta</surname><given-names>C.</given-names></name></person-group><article-title>Clinical lipidology ceramide as a target of chemotherapy: Its role in apoptosis and autophagy</article-title><source>Clin. Lipidol.</source><year>2017</year><volume>7</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.2217/clp.11.71</pub-id></element-citation></ref><ref id="B91-ijms-20-00372"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinton</surname><given-names>P.</given-names></name><name><surname>Giorgi</surname><given-names>C.</given-names></name><name><surname>Siviero</surname><given-names>R.</given-names></name><name><surname>Zecchini</surname><given-names>E.</given-names></name><name><surname>Rizzuto</surname><given-names>R.</given-names></name></person-group><article-title>Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>6407</fpage><lpage>6418</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.308</pub-id><pub-id pub-id-type="pmid">18955969</pub-id></element-citation></ref><ref id="B92-ijms-20-00372"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwang</surname><given-names>S.A.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name><name><surname>Krishnan</surname><given-names>K.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>&#x003b3;-tocotrienol inhibits nuclear factor-&#x003ba;B signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>809</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">17114179</pub-id></element-citation></ref><ref id="B93-ijms-20-00372"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>B.</given-names></name><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Krishnan</surname><given-names>S.</given-names></name><name><surname>Guha</surname><given-names>S.</given-names></name></person-group><article-title>Prevention and treatment of colorectal cancer by natural agents from mother nature</article-title><source>Curr. Colorectal Cancer Rep.</source><year>2013</year><volume>9</volume><fpage>37</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1007/s11888-012-0154-1</pub-id><?supplied-pmid 23814530?><pub-id pub-id-type="pmid">23814530</pub-id></element-citation></ref><ref id="B94-ijms-20-00372"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>S.E.</given-names></name><name><surname>Whaley</surname><given-names>S.G.</given-names></name><name><surname>Phillips</surname><given-names>R.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name><name><surname>Stimmel</surname><given-names>J.B.</given-names></name><name><surname>Leesnitzer</surname><given-names>L.</given-names></name><name><surname>Blanchard</surname><given-names>S.G.</given-names></name><name><surname>Stone</surname><given-names>W.L.</given-names></name><name><surname>Muenyi</surname><given-names>C.</given-names></name><name><surname>Krishnan</surname><given-names>K.</given-names></name></person-group><article-title>Gamma tocotrienol and prostate cancer: The regulation of two independent pathways to potentiate cell growth inhibition and apoptosis</article-title><source>J. Oil Palm Res.</source><year>2008</year><fpage>33</fpage><lpage>43</lpage></element-citation></ref><ref id="B95-ijms-20-00372"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>S.J.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name></person-group><article-title>Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity</article-title><source>Exp. Biol. Med.</source><year>2005</year><volume>230</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1177/153537020523000402</pub-id></element-citation></ref><ref id="B96-ijms-20-00372"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasinghe</surname><given-names>L.D.</given-names></name><name><surname>Gupta</surname><given-names>S.V.</given-names></name></person-group><article-title>Tocotrienol-rich mixture inhibits cell proliferation and induces apoptosis via down-regulation of the Notch-1/NF-&#x003ba;B pathways in NSCLC cells</article-title><source>Nutr. Diet. Suppl.</source><year>2017</year><volume>9</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.2147/NDS.S129891</pub-id></element-citation></ref><ref id="B97-ijms-20-00372"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kani</surname><given-names>K.</given-names></name><name><surname>Momota</surname><given-names>Y.</given-names></name><name><surname>Harada</surname><given-names>M.</given-names></name><name><surname>Yamamura</surname><given-names>Y.</given-names></name><name><surname>Aota</surname><given-names>K.</given-names></name><name><surname>Yamanoi</surname><given-names>T.</given-names></name><name><surname>Takano</surname><given-names>H.</given-names></name><name><surname>Motegi</surname><given-names>K.</given-names></name><name><surname>Azuma</surname><given-names>M.</given-names></name></person-group><article-title>&#x003b3;-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-&#x003ba;B-regulated anti-apoptotic gene products</article-title><source>Int. J. Oncol.</source><year>2013</year><volume>42</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.3892/ijo.2012.1692</pub-id><pub-id pub-id-type="pmid">23138939</pub-id></element-citation></ref><ref id="B98-ijms-20-00372"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunnumakkara</surname><given-names>A.B.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Ravindran</surname><given-names>J.</given-names></name><name><surname>Diagaradjane</surname><given-names>P.</given-names></name><name><surname>Deorukhkar</surname><given-names>A.</given-names></name><name><surname>Dey</surname><given-names>S.</given-names></name><name><surname>Koca</surname><given-names>C.</given-names></name><name><surname>Yadav</surname><given-names>V.R.</given-names></name><name><surname>Tong</surname><given-names>Z.</given-names></name><name><surname>Gelovani</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Gamma-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>8695</fpage><lpage>8705</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2318</pub-id><?supplied-pmid 20864511?><pub-id pub-id-type="pmid">20864511</pub-id></element-citation></ref><ref id="B99-ijms-20-00372"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>K.</given-names></name><name><surname>Francois</surname><given-names>R.A.</given-names></name><name><surname>Yamauchi</surname><given-names>T.</given-names></name><name><surname>Perez</surname><given-names>M.</given-names></name><name><surname>Sebti</surname><given-names>S.M.</given-names></name><name><surname>Malafa</surname><given-names>M.P.</given-names></name></person-group><article-title>Vitamin E &#x003b4;-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kB activation in pancreatic cancer</article-title><source>Mol. Cancer Ther.</source><year>2011</year><volume>10</volume><fpage>2363</fpage><lpage>2372</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0424</pub-id><pub-id pub-id-type="pmid">21971120</pub-id></element-citation></ref><ref id="B100-ijms-20-00372"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manu</surname><given-names>K.A.</given-names></name><name><surname>Shanmugam</surname><given-names>M.K.</given-names></name><name><surname>Ramachandran</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Fong</surname><given-names>C.W.</given-names></name><name><surname>Kumar</surname><given-names>A.P.</given-names></name><name><surname>Tan</surname><given-names>P.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name></person-group><article-title>First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kappaB pathway</article-title><source>Clin Cancer Res.</source><year>2012</year><volume>18</volume><fpage>2220</fpage><lpage>2229</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2470</pub-id><pub-id pub-id-type="pmid">22351692</pub-id></element-citation></ref><ref id="B101-ijms-20-00372"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>G.</given-names></name><name><surname>Ouyang</surname><given-names>G.</given-names></name><name><surname>Bao</surname><given-names>S.</given-names></name></person-group><article-title>The activation of Akt/PKB signaling pathway and cell survival</article-title><source>J. Cell. Mol. Med.</source><year>2005</year><volume>9</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2005.tb00337.x</pub-id><pub-id pub-id-type="pmid">15784165</pub-id></element-citation></ref><ref id="B102-ijms-20-00372"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samant</surname><given-names>G.V.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name></person-group><article-title>Gamma-tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells</article-title><source>Cell Prolif.</source><year>2006</year><volume>39</volume><fpage>563</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2184.2006.00412.x</pub-id><pub-id pub-id-type="pmid">17109639</pub-id></element-citation></ref><ref id="B103-ijms-20-00372"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sylvester</surname><given-names>P.W.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name></person-group><article-title>Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells</article-title><source>Asia Pac. J. Clin. Nutr.</source><year>2005</year><volume>14</volume><fpage>366</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">16326643</pub-id></element-citation></ref><ref id="B104-ijms-20-00372"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sylvester</surname><given-names>P.W.</given-names></name><name><surname>Ayoub</surname><given-names>N.M.</given-names></name></person-group><article-title>Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy</article-title><source>Anticancer Agents Med. Chem.</source><year>2013</year><volume>13</volume><fpage>1039</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.2174/18715206113139990116</pub-id><?supplied-pmid 23272909?><pub-id pub-id-type="pmid">23272909</pub-id></element-citation></ref><ref id="B105-ijms-20-00372"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin-Kang</surname><given-names>S.</given-names></name><name><surname>Ramsauer</surname><given-names>V.P.</given-names></name><name><surname>Lightner</surname><given-names>J.</given-names></name><name><surname>Chakraborty</surname><given-names>K.</given-names></name><name><surname>Stone</surname><given-names>W.</given-names></name><name><surname>Campbell</surname><given-names>S.</given-names></name><name><surname>Reddy</surname><given-names>S.A.</given-names></name><name><surname>Krishnan</surname><given-names>K.</given-names></name></person-group><article-title>Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway</article-title><source>Free Radic. Biol. Med.</source><year>2011</year><volume>51</volume><fpage>1164</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.06.008</pub-id><pub-id pub-id-type="pmid">21723941</pub-id></element-citation></ref><ref id="B106-ijms-20-00372"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>X.</given-names></name><name><surname>Kong</surname><given-names>N.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name><name><surname>Pan</surname><given-names>H.</given-names></name></person-group><article-title>JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents</article-title><source>Cancer Lett.</source><year>2014</year><volume>344</volume><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.11.019</pub-id><pub-id pub-id-type="pmid">24333738</pub-id></element-citation></ref><ref id="B107-ijms-20-00372"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>T.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name></person-group><article-title>Mitogen-activated protein kinases in apoptosis regulation</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>2838</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207556</pub-id><?supplied-pmid 15077147?><pub-id pub-id-type="pmid">15077147</pub-id></element-citation></ref><ref id="B108-ijms-20-00372"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koul</surname><given-names>H.K.</given-names></name><name><surname>Pal</surname><given-names>M.</given-names></name><name><surname>Koul</surname><given-names>S.</given-names></name></person-group><article-title>Role of p38 MAP kinase signal transduction in solid tumors</article-title><source>Genes Cancer</source><year>2013</year><volume>4</volume><fpage>342</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1177/1947601913507951</pub-id><pub-id pub-id-type="pmid">24349632</pub-id></element-citation></ref><ref id="B109-ijms-20-00372"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mebratu</surname><given-names>Y.</given-names></name><name><surname>Tesfaigzi</surname><given-names>Y.</given-names></name></person-group><article-title>How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?</article-title><source>Cell Cycle</source><year>2009</year><volume>8</volume><fpage>1168</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.4161/cc.8.8.8147</pub-id><?supplied-pmid 19282669?><pub-id pub-id-type="pmid">19282669</pub-id></element-citation></ref><ref id="B110-ijms-20-00372"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehud</surname><given-names>W.</given-names></name><name><surname>Rony</surname><given-names>S.</given-names></name></person-group><article-title>The dynamic subcellular localization of ERK: Mechanisms of translocation and role in various organelles</article-title><source>Curr. Opin. Cell Biol.</source><year>2016</year><volume>39</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">26827288</pub-id></element-citation></ref><ref id="B111-ijms-20-00372"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>T.</given-names></name><name><surname>Rindtorff</surname><given-names>N.</given-names></name><name><surname>Boutros</surname><given-names>M.</given-names></name></person-group><article-title>Wnt signaling in cancer</article-title><source>Oncogene</source><year>2017</year><volume>36</volume><fpage>1461</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.304</pub-id><pub-id pub-id-type="pmid">27617575</pub-id></element-citation></ref><ref id="B112-ijms-20-00372"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehrke</surname><given-names>I.</given-names></name><name><surname>Gandhirajan</surname><given-names>R.K.</given-names></name><name><surname>Kreuzer</surname><given-names>K.A.</given-names></name></person-group><article-title>Targeting the WNT/&#x003b2;-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options</article-title><source>Eur. J. Cancer</source><year>2009</year><volume>45</volume><fpage>2759</fpage><lpage>2767</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2009.08.003</pub-id><pub-id pub-id-type="pmid">19729298</pub-id></element-citation></ref><ref id="B113-ijms-20-00372"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Mo</surname><given-names>J.</given-names></name><name><surname>Jia</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Luan</surname><given-names>Z.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name></person-group><article-title>Activation of Wnt signaling inhibits the pro-apoptotic role of Notch in gastric cancer cells</article-title><source>Mol. Med. Rep.</source><year>2013</year><volume>7</volume><fpage>1751</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.3892/mmr.2013.1412</pub-id><?supplied-pmid 23563575?><pub-id pub-id-type="pmid">23563575</pub-id></element-citation></ref><ref id="B114-ijms-20-00372"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Experimental study on delta-tocotrienol inhibits the Wnt pathway in the colon cancer cell SW620</article-title><source>Wei Sheng Yan Jiu</source><year>2012</year><volume>41</volume><fpage>900</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">23424864</pub-id></element-citation></ref><ref id="B115-ijms-20-00372"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>R.A.</given-names></name><name><surname>Alawin</surname><given-names>O.A.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol reversal of epithelial-to-mesenchymal transition in human breast cancer cells is associated with inhibition of canonical Wnt signalling</article-title><source>Cell Prolif.</source><year>2016</year><volume>49</volume><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1111/cpr.12270</pub-id><?supplied-pmid 27323693?><pub-id pub-id-type="pmid">27323693</pub-id></element-citation></ref><ref id="B116-ijms-20-00372"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>C.K.</given-names></name><name><surname>Khanna</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>S.</given-names></name></person-group><article-title>Tocotrienols: Vitamin E beyond tocopherols</article-title><source>Life Sci.</source><year>2006</year><volume>78</volume><fpage>2088</fpage><lpage>2098</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2005.12.001</pub-id><?supplied-pmid 16458936?><pub-id pub-id-type="pmid">16458936</pub-id></element-citation></ref><ref id="B117-ijms-20-00372"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J.Y.</given-names></name><name><surname>Che</surname><given-names>H.L.</given-names></name><name><surname>Tan</surname><given-names>D.M.Y.</given-names></name><name><surname>Teng</surname><given-names>K.T.</given-names></name></person-group><article-title>Bioavailability of tocotrienols: Evidence in human studies</article-title><source>Nutr. Metab.</source><year>2014</year><volume>11</volume><pub-id pub-id-type="doi">10.1186/1743-7075-11-5</pub-id><?supplied-pmid 24410975?><pub-id pub-id-type="pmid">24410975</pub-id></element-citation></ref><ref id="B118-ijms-20-00372"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abuasal</surname><given-names>B.S.</given-names></name><name><surname>Lucas</surname><given-names>C.</given-names></name><name><surname>Peyton</surname><given-names>B.</given-names></name><name><surname>Alayoubi</surname><given-names>A.</given-names></name><name><surname>Nazzal</surname><given-names>S.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name><name><surname>Kaddoumi</surname><given-names>A.</given-names></name></person-group><article-title>Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases &#x003b3;-tocotrienol oral bioavailability</article-title><source>Lipids</source><year>2012</year><volume>47</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1007/s11745-012-3655-4</pub-id><?supplied-pmid 22271424?><pub-id pub-id-type="pmid">22271424</pub-id></element-citation></ref><ref id="B119-ijms-20-00372"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Fayyad</surname><given-names>A.</given-names></name><name><surname>Lucas</surname><given-names>C.</given-names></name><name><surname>Peyton</surname><given-names>B.</given-names></name><name><surname>Alayoubi</surname><given-names>A.</given-names></name><name><surname>Nazzal</surname><given-names>S.</given-names></name><name><surname>Sylvester</surname><given-names>P.W.</given-names></name><name><surname>Kaddoumi</surname><given-names>A.</given-names></name></person-group><article-title>PEGylated &#x003b3;-tocotrienol isomer of vitamin E: Synthesis, characterization, in vitro cytotoxicity, and oral bioavailability</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2015</year><volume>96</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.07.022</pub-id><pub-id pub-id-type="pmid">26235392</pub-id></element-citation></ref><ref id="B120-ijms-20-00372"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>D.M.Y.</given-names></name><name><surname>Fu</surname><given-names>J.Y.</given-names></name><name><surname>Wong</surname><given-names>F.S.</given-names></name><name><surname>Er</surname><given-names>H.M.</given-names></name><name><surname>Chen</surname><given-names>Y.S.</given-names></name><name><surname>Nesaretnam</surname><given-names>K.</given-names></name></person-group><article-title>Tumor regression and modulation of gene expression via tumor-targeted tocotrienol niosomes</article-title><source>Nanomedicine</source><year>2017</year><volume>12</volume><fpage>2487</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.2217/nnm-2017-0182</pub-id><pub-id pub-id-type="pmid">28972460</pub-id></element-citation></ref><ref id="B121-ijms-20-00372"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>J.</given-names></name><name><surname>Nayel</surname><given-names>A.</given-names></name><name><surname>Hoang</surname><given-names>C.</given-names></name><name><surname>Elbayoumi</surname><given-names>T.</given-names></name></person-group><article-title>Enhanced effectiveness of tocotrienol-based nano-emulsified system for topical delivery against skin carcinomas</article-title><source>Drug Deliv.</source><year>2016</year><volume>23</volume><fpage>1514</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.3109/10717544.2014.966925</pub-id><pub-id pub-id-type="pmid">25293973</pub-id></element-citation></ref><ref id="B122-ijms-20-00372"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viola</surname><given-names>V.</given-names></name><name><surname>Pilolli</surname><given-names>F.</given-names></name><name><surname>Piroddi</surname><given-names>M.</given-names></name><name><surname>Pierpaoli</surname><given-names>E.</given-names></name><name><surname>Orlando</surname><given-names>F.</given-names></name><name><surname>Provinciali</surname><given-names>M.</given-names></name><name><surname>Betti</surname><given-names>M.</given-names></name><name><surname>Mazzini</surname><given-names>F.</given-names></name><name><surname>Galli</surname><given-names>F.</given-names></name></person-group><article-title>Why tocotrienols work better: Insights into the in vitro anti-cancer mechanism of vitamin E</article-title><source>Genes Nutr.</source><year>2012</year><volume>7</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s12263-011-0219-9</pub-id><pub-id pub-id-type="pmid">21505906</pub-id></element-citation></ref><ref id="B123-ijms-20-00372"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Tabb</surname><given-names>M.M.</given-names></name><name><surname>Sadatrafiei</surname><given-names>A.</given-names></name><name><surname>Gr&#x000fc;n</surname><given-names>F.</given-names></name><name><surname>Blumberg</surname><given-names>B.</given-names></name></person-group><article-title>Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes</article-title><source>Drug Metab. Dispos.</source><year>2004</year><volume>32</volume><fpage>1075</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.000299</pub-id><?supplied-pmid 15269186?><pub-id pub-id-type="pmid">15269186</pub-id></element-citation></ref><ref id="B124-ijms-20-00372"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brigelius-Floh&#x000e9;</surname><given-names>R.</given-names></name></person-group><article-title>Induction of drug metabolizing enzymes by vitamin E</article-title><source>J. Plant Physiol.</source><year>2005</year><volume>162</volume><fpage>797</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/j.jplph.2005.04.013</pub-id><pub-id pub-id-type="pmid">16008107</pub-id></element-citation></ref><ref id="B125-ijms-20-00372"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.H.</given-names></name><name><surname>Zhang</surname><given-names>X.S.</given-names></name></person-group><article-title>Targeted therapy: Resistance and re-sensitization</article-title><source>Chin. J. Cancer</source><year>2015</year><volume>34</volume><fpage>496</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1186/s40880-015-0047-1</pub-id><?supplied-pmid 26370727?><pub-id pub-id-type="pmid">26370727</pub-id></element-citation></ref><ref id="B126-ijms-20-00372"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melisi</surname><given-names>D.</given-names></name><name><surname>Piro</surname><given-names>G.</given-names></name><name><surname>Tamburrino</surname><given-names>A.</given-names></name><name><surname>Carbone</surname><given-names>C.</given-names></name><name><surname>Tortora</surname><given-names>G.</given-names></name></person-group><article-title>Rationale and clinical use of multitargeting anticancer agents</article-title><source>Curr. Opin. Pharmacol.</source><year>2013</year><volume>13</volume><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2013.06.012</pub-id><pub-id pub-id-type="pmid">23856428</pub-id></element-citation></ref><ref id="B127-ijms-20-00372"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>A.S.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>Polypharmacology: Drug discovery for the future</article-title><source>Expert Rev. Clin. Pharmacol.</source><year>2013</year><volume>6</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1586/ecp.12.74</pub-id><?supplied-pmid 23272792?><pub-id pub-id-type="pmid">23272792</pub-id></element-citation></ref><ref id="B128-ijms-20-00372"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eitsuka</surname><given-names>T.</given-names></name><name><surname>Tatewaki</surname><given-names>N.</given-names></name><name><surname>Nishida</surname><given-names>H.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Miyazawa</surname><given-names>T.</given-names></name></person-group><article-title>Synergistic anticancer effect of tocotrienol combined with chemotherapeutic agents or dietary components: A review</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>1605</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17101605</pub-id></element-citation></ref><ref id="B129-ijms-20-00372"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Springett</surname><given-names>G.M.</given-names></name><name><surname>Husain</surname><given-names>K.</given-names></name><name><surname>Neuger</surname><given-names>A.</given-names></name><name><surname>Centeno</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Hutchinson</surname><given-names>T.Z.</given-names></name><name><surname>Lush</surname><given-names>R.M.</given-names></name><name><surname>Sebti</surname><given-names>S.</given-names></name><name><surname>Malafa</surname><given-names>M.P.</given-names></name></person-group><article-title>A Phase I safety, pharmacokinetic, and pharmacodynamic presurgical trial of vitamin E delta-tocotrienol in patients with pancreatic ductal neoplasia</article-title><source>EBioMedicine</source><year>2015</year><volume>2</volume><fpage>1987</fpage><lpage>1995</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2015.11.025</pub-id><?supplied-pmid 26844278?><pub-id pub-id-type="pmid">26844278</pub-id></element-citation></ref><ref id="B130-ijms-20-00372"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.S.</given-names></name><name><surname>Li</surname><given-names>D.M.</given-names></name><name><surname>He</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>Y.H.</given-names></name><name><surname>Wang</surname><given-names>C.H.</given-names></name><name><surname>Jiang</surname><given-names>S.Q.</given-names></name><name><surname>Chen</surname><given-names>B.Q.</given-names></name><name><surname>Liu</surname><given-names>J.R.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol induces paraptosis-like cell death in human colon carcinoma SW620 Cells</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e57779</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0057779</pub-id><pub-id pub-id-type="pmid">23469066</pub-id></element-citation></ref><ref id="B131-ijms-20-00372"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.S.</given-names></name><name><surname>Li</surname><given-names>D.M.</given-names></name><name><surname>He</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>Y.H.</given-names></name><name><surname>Wang</surname><given-names>C.H.</given-names></name><name><surname>Jiang</surname><given-names>S.Q.</given-names></name><name><surname>Chen</surname><given-names>B.Q.</given-names></name><name><surname>Liu</surname><given-names>J.R.</given-names></name></person-group><article-title>A paraptosis-like cell death induced by &#x003b4;-tocotrienol in human colon carcinoma SW620 cells is associated with the suppression of the Wnt signaling pathway</article-title><source>Toxicology</source><year>2011</year><volume>285</volume><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2011.03.011</pub-id><pub-id pub-id-type="pmid">21453743</pub-id></element-citation></ref><ref id="B132-ijms-20-00372"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Khattouti</surname><given-names>A.</given-names></name><name><surname>Selimovic</surname><given-names>D.</given-names></name><name><surname>Haikel</surname><given-names>Y.</given-names></name><name><surname>Hassan</surname><given-names>M.</given-names></name></person-group><article-title>Crosstalk between apoptosis and autophagy: Molecular mechanisms and therapeutic strategies in cancer</article-title><source>J. Cell Death</source><year>2013</year><volume>6</volume><fpage>37</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.4137/JCD.S11034</pub-id><pub-id pub-id-type="pmid">25278778</pub-id></element-citation></ref><ref id="B133-ijms-20-00372"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhuang</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Q.</given-names></name><name><surname>Chang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>B.</given-names></name><etal/></person-group><article-title>&#x003b4;-tocotrienol induces human bladder cancer cell growth arrest, apoptosis and chemosensitization through inhibition of STAT3 pathway</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0122712</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0122712</pub-id><pub-id pub-id-type="pmid">25849286</pub-id></element-citation></ref><ref id="B134-ijms-20-00372"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S.W.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name><name><surname>Ting</surname><given-names>K.N.</given-names></name><name><surname>Bradshaw</surname><given-names>T.D.</given-names></name><name><surname>Zeenathul</surname><given-names>N.A.</given-names></name></person-group><article-title>Antiproliferation and induction of caspase-8-dependent mitochondria-mediated apoptosis by &#x003b2;-tocotrienol in human lung and brain cancer cell lines</article-title><source>Biomed. Pharmacother.</source><year>2014</year><volume>68</volume><fpage>1105</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2014.10.006</pub-id><?supplied-pmid 25456851?><pub-id pub-id-type="pmid">25456851</pub-id></element-citation></ref><ref id="B135-ijms-20-00372"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loganathan</surname><given-names>R.</given-names></name><name><surname>Selvaduray</surname><given-names>K.R.</given-names></name><name><surname>Nesaretnam</surname><given-names>K.</given-names></name><name><surname>Radhakrishnan</surname><given-names>A.K.</given-names></name></person-group><article-title>Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity</article-title><source>Cell Prolif.</source><year>2013</year><volume>46</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1111/cpr.12014</pub-id><?supplied-pmid 23510475?><pub-id pub-id-type="pmid">23510475</pub-id></element-citation></ref><ref id="B136-ijms-20-00372"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Ju</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Tong</surname><given-names>Z.</given-names></name></person-group><article-title>miR-429 mediates &#x003b4;-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP</article-title><source>Int. J. Clin. Exp. Med.</source><year>2015</year><volume>8</volume><fpage>15648</fpage><lpage>15656</lpage><?supplied-pmid 26629059?><pub-id pub-id-type="pmid">26629059</pub-id></element-citation></ref><ref id="B137-ijms-20-00372"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comitato</surname><given-names>R.</given-names></name><name><surname>Leoni</surname><given-names>G.</given-names></name><name><surname>Canali</surname><given-names>R.</given-names></name><name><surname>Ambra</surname><given-names>R.</given-names></name><name><surname>Nesaretnam</surname><given-names>K.</given-names></name><name><surname>Virgili</surname><given-names>F.</given-names></name></person-group><article-title>Tocotrienols activity in MCF-7 breast cancer cells: Involvement of ER&#x003b2; signal transduction</article-title><source>Mol. Nutr. Food Res.</source><year>2010</year><volume>54</volume><fpage>669</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1002/mnfr.200900383</pub-id><?supplied-pmid 20306477?><pub-id pub-id-type="pmid">20306477</pub-id></element-citation></ref><ref id="B138-ijms-20-00372"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viola</surname><given-names>V.</given-names></name><name><surname>Ciffolilli</surname><given-names>S.</given-names></name><name><surname>Legnaioli</surname><given-names>S.</given-names></name><name><surname>Piroddi</surname><given-names>M.</given-names></name><name><surname>Betti</surname><given-names>M.</given-names></name><name><surname>Mazzini</surname><given-names>F.</given-names></name><name><surname>Pierpaoli</surname><given-names>E.</given-names></name><name><surname>Provinciali</surname><given-names>M.</given-names></name><name><surname>Galli</surname><given-names>F.</given-names></name></person-group><article-title>Mitochondrial-dependent anticancer activity of &#x003b4;-tocotrienol and its synthetic derivatives in HER-2/neu overexpressing breast adenocarcinoma cells</article-title><source>BioFactors</source><year>2013</year><volume>39</volume><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1002/biof.1089</pub-id><?supplied-pmid 23361894?><pub-id pub-id-type="pmid">23361894</pub-id></element-citation></ref><ref id="B139-ijms-20-00372"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shun</surname><given-names>M.C.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Gapor</surname><given-names>A.</given-names></name><name><surname>Parsons</surname><given-names>R.</given-names></name><name><surname>Atkinson</surname><given-names>J.</given-names></name><name><surname>Sanders</surname><given-names>B.G.</given-names></name><name><surname>Kline</surname><given-names>K.</given-names></name></person-group><article-title>Pro-apoptotic mechanisms of action of a novel vitamin E analog (&#x003b1;-TEA) and a naturally occurring form of vitamin E (&#x003b4;-Tocotrienol) in MDA-MB-435 human breast cancer cells</article-title><source>Nutr. Cancer</source><year>2004</year><volume>48</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1207/s15327914nc4801_13</pub-id><pub-id pub-id-type="pmid">15203383</pub-id></element-citation></ref><ref id="B140-ijms-20-00372"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S.J.</given-names></name><name><surname>Ng</surname><given-names>L.T.</given-names></name></person-group><article-title>Tocotrienols inhibited growth and induced apoptosis in human HeLa cells through the cell cycle signaling pathway</article-title><source>Integr. Cancer Ther.</source><year>2010</year><volume>9</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1177/1534735409357757</pub-id><pub-id pub-id-type="pmid">20150225</pub-id></element-citation></ref><ref id="B141-ijms-20-00372"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasani</surname><given-names>N.A.</given-names></name><name><surname>Yusoff</surname><given-names>P.A.</given-names></name><name><surname>Bak</surname><given-names>K.</given-names></name><name><surname>Abdul-Gapor</surname><given-names>M.T.</given-names></name><name><surname>Wan-Ngah</surname><given-names>W.Z.</given-names></name></person-group><article-title>The possible mechanism of action of palm oil &#x003b3;-tocotrienol and &#x003b1;-tocopherol on the cervical carcinoma CaSki cell apoptosis</article-title><source>Biomed. Res.</source><year>2008</year><volume>19</volume><fpage>194</fpage><lpage>200</lpage></element-citation></ref><ref id="B142-ijms-20-00372"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasani</surname><given-names>N.A.</given-names></name><name><surname>Bak</surname><given-names>K.</given-names></name><name><surname>Wan Ngah</surname><given-names>W.Z.</given-names></name></person-group><article-title>The anti proliferative effect of palm oil &#x003b3;-tocotrienol involves alterations in MEK-2 and ERK-2 protein expressions in CaSki cells</article-title><source>Asian Biomed.</source><year>2011</year><volume>5</volume><fpage>601</fpage><lpage>609</lpage></element-citation></ref><ref id="B143-ijms-20-00372"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Hang</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Koo</surname><given-names>P.T.</given-names></name><name><surname>Tsang</surname><given-names>D.J.</given-names></name><name><surname>Yang</surname><given-names>C.S.</given-names></name></person-group><article-title>Synergistic actions of atorvastatin with &#x003b3;-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells</article-title><source>Int. J. Cancer</source><year>2010</year><volume>126</volume><fpage>852</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1002/ijc.24766</pub-id><?supplied-pmid 19626588?><pub-id pub-id-type="pmid">19626588</pub-id></element-citation></ref><ref id="B144-ijms-20-00372"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>A.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Sookwong</surname><given-names>P.</given-names></name><name><surname>Tsuduki</surname><given-names>T.</given-names></name><name><surname>Asai</surname><given-names>A.</given-names></name><name><surname>Miyazawa</surname><given-names>T.</given-names></name></person-group><article-title>&#x003b1;-Tocopherol attenuates the cytotoxic effect of &#x003b4;-tocotrienol in human colorectal adenocarcinoma cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2010</year><volume>397</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.05.087</pub-id><pub-id pub-id-type="pmid">20493172</pub-id></element-citation></ref><ref id="B145-ijms-20-00372"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eitsuka</surname><given-names>T.</given-names></name><name><surname>Tatewaki</surname><given-names>N.</given-names></name><name><surname>Nishida</surname><given-names>H.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Miyazawa</surname><given-names>T.</given-names></name></person-group><article-title>A combination of d-tocotrienol and ferulic acid synergistically inhibits telomerase activity in DLD-1 human colorectal adenocarcinoma cells</article-title><source>J. Nutr. Sci. Vitaminol.</source><year>2016</year><volume>62</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.3177/jnsv.62.281</pub-id><?supplied-pmid 27928113?><pub-id pub-id-type="pmid">27928113</pub-id></element-citation></ref><ref id="B146-ijms-20-00372"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eitsuka</surname><given-names>T.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Miyazawa</surname><given-names>T.</given-names></name></person-group><article-title>Down-regulation of telomerase activity in DLD-1 human colorectal adenocarcinoma cells by tocotrienol</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2006</year><volume>348</volume><fpage>170</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.07.029</pub-id><?supplied-pmid 16875674?><pub-id pub-id-type="pmid">16875674</pub-id></element-citation></ref><ref id="B147-ijms-20-00372"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling</article-title><source>Br. J. Nutr.</source><year>2008</year><volume>99</volume><fpage>1247</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1017/S0007114507879128</pub-id><?supplied-pmid 18081943?><pub-id pub-id-type="pmid">18081943</pub-id></element-citation></ref><ref id="B148-ijms-20-00372"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>&#x003b3;-Tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells</article-title><source>J. Nutr. Biochem.</source><year>2009</year><volume>20</volume><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2008.03.003</pub-id><pub-id pub-id-type="pmid">18602811</pub-id></element-citation></ref><ref id="B149-ijms-20-00372"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasinghe</surname><given-names>L.D.</given-names></name><name><surname>Pindiprolu</surname><given-names>R.H.</given-names></name><name><surname>Gupta</surname><given-names>S.V.</given-names></name></person-group><article-title>Delta-tocotrienol inhibits non-small-cell lung cancer cell invasion via the inhibition of NF-&#x003ba;B, uPA activator, and MMP-9</article-title><source>Onco-Targets Ther.</source><year>2018</year><volume>11</volume><fpage>4301</fpage><lpage>4314</lpage><pub-id pub-id-type="doi">10.2147/OTT.S160163</pub-id><pub-id pub-id-type="pmid">30100736</pub-id></element-citation></ref><ref id="B150-ijms-20-00372"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Sarkar</surname><given-names>F.H.</given-names></name><name><surname>Gupta</surname><given-names>S.V.</given-names></name></person-group><article-title>Delta-tocotrienol augments cisplatin-induced suppression of non-small cell lung cancer cells via inhibition of the Notch-1 pathway</article-title><source>Anticancer Res.</source><year>2012</year><volume>32</volume><fpage>2647</fpage><lpage>2656</lpage><pub-id pub-id-type="pmid">22753722</pub-id></element-citation></ref><ref id="B151-ijms-20-00372"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>K.</given-names></name><name><surname>Centeno</surname><given-names>B.A.</given-names></name><name><surname>Coppola</surname><given-names>D.</given-names></name><name><surname>Trevino</surname><given-names>J.</given-names></name><name><surname>Sebti</surname><given-names>S.M.</given-names></name><name><surname>Malafa</surname><given-names>M.P.</given-names></name></person-group><article-title>&#x003b4;-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>31554</fpage><lpage>31567</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15767</pub-id><pub-id pub-id-type="pmid">28404939</pub-id></element-citation></ref><ref id="B152-ijms-20-00372"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodul</surname><given-names>P.J.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Husain</surname><given-names>K.</given-names></name><name><surname>Pimiento</surname><given-names>J.M.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Francois</surname><given-names>R.</given-names></name><name><surname>Pledger</surname><given-names>W.J.</given-names></name><name><surname>Coppola</surname><given-names>D.</given-names></name><name><surname>Sebti</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Vitamin E &#x003b4;-tocotrienol induces p27Kip1-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e52526</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0052526</pub-id><pub-id pub-id-type="pmid">23393547</pub-id></element-citation></ref><ref id="B153-ijms-20-00372"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eitsuka</surname><given-names>T.</given-names></name><name><surname>Tatewaki</surname><given-names>N.</given-names></name><name><surname>Nishida</surname><given-names>H.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Miyazawa</surname><given-names>T.</given-names></name></person-group><article-title>Synergistic inhibition of cancer cell proliferation with a combination of delta-tocotrienol and ferulic acid</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2014</year><volume>453</volume><fpage>606</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.09.126</pub-id><pub-id pub-id-type="pmid">25285637</pub-id></element-citation></ref><ref id="B154-ijms-20-00372"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>S.U.</given-names></name><name><surname>Yap</surname><given-names>W.N.</given-names></name><name><surname>Chiu</surname><given-names>Y.T.</given-names></name><name><surname>Lee</surname><given-names>D.T.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>T.K.</given-names></name><name><surname>Vasireddy</surname><given-names>R.S.</given-names></name><name><surname>Wong</surname><given-names>Y.C.</given-names></name><name><surname>Ching</surname><given-names>Y.P.</given-names></name><name><surname>Nelson</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population</article-title><source>Int. J. Cancer</source><year>2011</year><volume>128</volume><fpage>2182</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1002/ijc.25546</pub-id><?supplied-pmid 20617516?><pub-id pub-id-type="pmid">20617516</pub-id></element-citation></ref><ref id="B155-ijms-20-00372"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzagalli</surname><given-names>M.</given-names></name><name><surname>Moretti</surname><given-names>R.M.</given-names></name><name><surname>Messi</surname><given-names>E.</given-names></name><name><surname>Marelli</surname><given-names>M.M.</given-names></name><name><surname>Fontana</surname><given-names>F.</given-names></name><name><surname>Anastasia</surname><given-names>A.</given-names></name><name><surname>Bani</surname><given-names>M.R.</given-names></name><name><surname>Beretta</surname><given-names>G.</given-names></name><name><surname>Limonta</surname><given-names>P.</given-names></name></person-group><article-title>Targeting melanoma stem cells with the Vitamin E derivative &#x003b4;-tocotrienol</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><pub-id pub-id-type="doi">10.1038/s41598-017-19057-4</pub-id><?supplied-pmid 29330434?><pub-id pub-id-type="pmid">29330434</pub-id></element-citation></ref><ref id="B156-ijms-20-00372"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>L.T.</given-names></name><name><surname>Lin</surname><given-names>L.T.</given-names></name><name><surname>Chen</surname><given-names>C.L.</given-names></name><name><surname>Chen</surname><given-names>H.W.</given-names></name><name><surname>Wu</surname><given-names>S.J.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name></person-group><article-title>Anti-melanogenic effects of &#x003b4;-tocotrienol are associated with tyrosinase-related proteins and MAPK signaling pathway in B16 melanoma cells</article-title><source>Phytomedicine</source><year>2014</year><volume>21</volume><fpage>978</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2014.03.003</pub-id><?supplied-pmid 24680613?><pub-id pub-id-type="pmid">24680613</pub-id></element-citation></ref><ref id="B157-ijms-20-00372"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>S.</given-names></name><name><surname>Naito</surname><given-names>Y.</given-names></name><name><surname>Matsushita</surname><given-names>Y.</given-names></name><name><surname>Nouchi</surname><given-names>M.</given-names></name><name><surname>Kawai</surname><given-names>M.</given-names></name><name><surname>Minami</surname><given-names>E.</given-names></name><name><surname>Aoi</surname><given-names>W.</given-names></name><name><surname>Ikeda</surname><given-names>S.</given-names></name><name><surname>Higashi</surname><given-names>A.</given-names></name><name><surname>Yoshikawa</surname><given-names>T.</given-names></name></person-group><article-title>&#x003b4;-Tocotrienol suppresses tumorigenesis by inducing apoptosis and blocking the COX-2/PGE2 pathway that stimulates tumor&#x02013;stromal interactions in colon cancer</article-title><source>J. Funct. Foods</source><year>2017</year><volume>35</volume><fpage>428</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2017.06.002</pub-id></element-citation></ref><ref id="B158-ijms-20-00372"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>K.</given-names></name><name><surname>Centeno</surname><given-names>B.A.</given-names></name><name><surname>Chen</surname><given-names>D.T.</given-names></name><name><surname>Fulp</surname><given-names>W.J.</given-names></name><name><surname>Perez</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>G.Z.</given-names></name><name><surname>Luetteke</surname><given-names>N.</given-names></name><name><surname>Hingorani</surname><given-names>S.R.</given-names></name><name><surname>Sebti</surname><given-names>S.M.</given-names></name><name><surname>Malafa</surname><given-names>M.P.</given-names></name></person-group><article-title>Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-Kras; Pdx-1-Cre mice by vitamin E &#x003b4;-tocotrienol</article-title><source>Carcinogenesis</source><year>2013</year><volume>34</volume><fpage>858</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt002</pub-id><?supplied-pmid 23302291?><pub-id pub-id-type="pmid">23302291</pub-id></element-citation></ref><ref id="B159-ijms-20-00372"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>W.N.</given-names></name><name><surname>Zaiden</surname><given-names>N.</given-names></name><name><surname>Luk</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>D.T.</given-names></name><name><surname>Ling</surname><given-names>M.T.</given-names></name><name><surname>Wong</surname><given-names>Y.C.</given-names></name><name><surname>Yap</surname><given-names>Y.L.</given-names></name></person-group><article-title>In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer</article-title><source>Pharmacology</source><year>2010</year><volume>85</volume><fpage>248</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1159/000278205</pub-id><pub-id pub-id-type="pmid">20375535</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-20-00372-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Extrinsic and intrinsic pathways of apoptosis. The extrinsic pathway begins outside of a cell and involves the binding of extracellular death ligands to their respective transmembrane death receptors. The activation of tumor necrosis factor (TNF) receptor superfamily, such as first apoptosis signal (Fas), takes place, leading to activation of caspase-8 (initiator caspase) and recruitment of the Fas-associated protein with death domain (FADD) adapter molecule. It transduces a downstream signaling cascade to the effector caspase (caspase-8), leading to the proteolytic activation of caspase-3. In fact, the extrinsic pathway can cause amplification of cascade via intrinsic mitochondrial pathway whereby caspase-8 cleaves Bid to promote mitochondrial outer membrane permeabilization (MOMP) [<xref rid="B32-ijms-20-00372" ref-type="bibr">32</xref>]. The intrinsic pathway is initiated by internal stimuli, such as genetic damage, growth factor deprivation, hypoxia, oxidative stress, and flux of calcium ions (Ca<sup>2+</sup>) [<xref rid="B33-ijms-20-00372" ref-type="bibr">33</xref>]. The stimuli then perceive cell death signals via the mitochondrion, which represents the metabolic status of a cell. The MOMP is often regarded as the primary step required for activation of caspases. Proapoptotic and antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins are involved in regulating the permeability of outer mitochondrial membrane [<xref rid="B34-ijms-20-00372" ref-type="bibr">34</xref>,<xref rid="B35-ijms-20-00372" ref-type="bibr">35</xref>]. Upon apoptotic stimulus, MOMP takes place, leading to the release of cytochrome <italic>c</italic> from the intermembrane space. In the cytoplasm, cytochrome <italic>c</italic> engages apoptotic protease activating factor 1 (Apaf-1) and eventually leads to the activation of caspase-9 (initiator caspase). Following that, caspase-9 activates executioner caspases, such as caspase-3, -6, and -7, which subsequently cause the downstream biochemical events, leading to apoptosis [<xref rid="B36-ijms-20-00372" ref-type="bibr">36</xref>].</p></caption><graphic xlink:href="ijms-20-00372-g001"/></fig><fig id="ijms-20-00372-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The process of autophagy. During autophagy, phagophore (cup-shaped, double-membrane sac) emerges in cytoplasm, driven by unc-51-like kinase 1 (ULK1) complex and vacuolar protein sorting (Vps) 34 complex. The expansion of phagophore is facilitated by Atg5&#x02013;12/Atg16L complex to uptake cargos from the cytoplasm into a double-membrane autophagosome. The loaded autophagosome then fuses with lysosome to allow the degradation of cargo by lysosomal proteases, while microtubule-associated protein light chain 3 (LC3-I) will be recycled back to cytosol. The endogenous LC3-I, present in the cytoplasm, is processed to LC3-II and bound to the autophagosome during autophagy. Therefore, the ratio of LC3-I (water soluble) and LC3-II (lipidated) is often used as a marker to assess autophagy. Then, the lysosomal permeases and transporters export amino acids and other by-products of degradation back to the cytoplasm, where they can be reused for building macromolecules and for metabolism [<xref rid="B37-ijms-20-00372" ref-type="bibr">37</xref>]. Abbreviations: Atg, autophagy-related protein; FIP200, focal adhesion kinase family interacting protein of 200 kDa.</p></caption><graphic xlink:href="ijms-20-00372-g002"/></fig><fig id="ijms-20-00372-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Proposed actions of tocotrienols (T3) in inducing mitochondrial pathway of apoptosis. A: direct displacement of Bcl-2 molecule by acting as a BH3 mimetic; B: transcriptional regulation of <italic>Bax</italic> gene expression; C: inhibition of IAP family; D: induction of caspase-independent apoptotic pathway after mitochondrial damage. Abbreviations: Apaf-1, apoptotic protease activating factor 1; Bcl-2, B-cell lymphoma 2; Cas-, caspase-; MOMP, mitochondrial outer membrane permeabilization; IAP, inhibitor of apoptosis protein; PARP, poly(ADP-ribose) polymerase; ROS, reactive oxidative species; AIF, apoptosis inducing factor; HtrA, high temperature requirement A; EndoG, endonuclease G. &#x0201c;?&#x0201d; indicates more investigations are required.</p></caption><graphic xlink:href="ijms-20-00372-g003"/></fig><fig id="ijms-20-00372-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Overview of tocotrienols-induced ER-stress-mediated apoptosis. Tocotrienols interact with unknown receptor on cell surface to trigger ER stress. BiP dissociates from unfolded protein response (UPR) sensors (i.e., PERK, IRE1, and ATF6) to trigger the respective signaling pathways, leading to apoptosis. Abbreviations: BiP or GRP78, glucose-regulated protein; CHOP, CCAAT-enhancer-binding protein homologous protein; PERK, PKR-like ER-localized eIF2&#x003b1; kinase; IRE1, inositol-requiring enzyme 1; ATF, activating transcription factor; eIF2-&#x003b1;, eukaryotic initiation factor 2 alpha; Cas-, caspase-; PARP, poly(ADP-ribose) polymerase; sXBP1, spliced X-box binding protein 1, TRB3, tribbles 3. &#x0201c;?&#x0201d; indicates more investigations are required.</p></caption><graphic xlink:href="ijms-20-00372-g004"/></fig><fig id="ijms-20-00372-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Schematic representation of potential interactions between tocotrienols-induced apoptosis and autophagy. Tocotrienols bind to Bcl-2 protein to displace proapoptotic protein (i.e., Bax) and proautophagic protein (Beclin-1) to initiate apoptosis and autophagy, respectively. Bax initiates MOMP to induce apoptosis, leading to generation of ROS, which serves as a second messenger to trigger the expression of autophagy-related protein (Atg). Tocotrienols upregulate de novo synthesis of ceramides, which can activate JNK signaling by phosphorylating Bcl-2 family proteins and induce Ca<sup>2+</sup> release by ER stress, eventually resulting in apoptosis and autophagy. &#x0201c;?&#x0201d; indicates more investigations are required.</p></caption><graphic xlink:href="ijms-20-00372-g005"/></fig><fig id="ijms-20-00372-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Tocotrienols suppress cell survival signaling pathways in cancers.</p></caption><graphic xlink:href="ijms-20-00372-g006"/></fig><table-wrap id="ijms-20-00372-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-20-00372-t001_Table 1</object-id><label>Table 1</label><caption><p>Exemplar in vitro studies for elucidating the molecular targets of tocotrienols-induced cell death.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Molecular Target(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference(s)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bladder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T24<break/>5637<break/>J82<break/>UMUC-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p21, p27, Bax, caspase-3, cleaved PARP, SHP-1<break/>&#x02193; cyclin D1, Bcl-2, Bcl-xL, Mcl-1, ETK phosphorylation, STAT3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B133-ijms-20-00372" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U87MG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-8, Bid, cytochrome <italic>c</italic>, Bax</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-ijms-20-00372" ref-type="bibr">41</xref>,<xref rid="B134-ijms-20-00372" ref-type="bibr">134</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-231</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-8, caspase-9, caspase-7, caspase-3, cleaved PARP, DR5, DR4, p-JNK, p-c-Jun, p-p38, BiP, ATF3, ATF4, p-PERK, p-IRE1&#x003b1;, p-eIF2&#x003b1;, CHOP, LC3-II/I, Beclin-1, Bax<break/>&#x02193; NF-&#x003ba;B, cyclin D1, cyclin D3, CDK4, Bcl-2, PI3K, p-AKT, p-mTOR, XIAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-ijms-20-00372" ref-type="bibr">69</xref>,<xref rid="B73-ijms-20-00372" ref-type="bibr">73</xref>,<xref rid="B88-ijms-20-00372" ref-type="bibr">88</xref>,<xref rid="B135-ijms-20-00372" ref-type="bibr">135</xref>,<xref rid="B136-ijms-20-00372" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCF-7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-8, caspase-9, caspase-7, caspase-3, Bax, cleaved PARP, ATF3, BiP, CHOP, p-PERK, p-IRE1&#x003b1;, p-EIF2&#x003b1;, ATF4, LC3-II/I, Beclin-1, DR5, p-JNK, p-c-Jun, p-p38, MIC-1, EGR-1, cathepsin D<break/>&#x02193; cyclin D1, cyclin D3, CDK4, NF-&#x003ba;B, Bcl-2, PI3K, p-AKT, p-mTOR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-ijms-20-00372" ref-type="bibr">69</xref>,<xref rid="B70-ijms-20-00372" ref-type="bibr">70</xref>,<xref rid="B73-ijms-20-00372" ref-type="bibr">73</xref>,<xref rid="B88-ijms-20-00372" ref-type="bibr">88</xref>,<xref rid="B136-ijms-20-00372" ref-type="bibr">136</xref>,<xref rid="B137-ijms-20-00372" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+SA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; LC3-II/I, Beclin-1, Bax, cleaved PARP, cleaved caspase-3<break/>&#x02193; Bcl-2, PI3K, p-AKT, p-mTOR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-ijms-20-00372" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SKBR3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; p-ERK1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-ijms-20-00372" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDA-MB-435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; cleaved PARP, p-JNK-1, JNK1, p-c-Jun, c-Jun, TGF&#x003b2;RII, TGF&#x003b2;RI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-ijms-20-00372" ref-type="bibr">139</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cervix</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HeLa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; Bax, cytochrome <italic>c</italic>, caspase-12, caspase-9, caspase-8, caspase-3, IL-6, XBP-1, p-IRE-1&#x003b1;, BiP, CHOP, XBP-1, cleaved PARP<break/>&#x02193; PCNA, cyclin D3, p16, CDK6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-ijms-20-00372" ref-type="bibr">46</xref>,<xref rid="B47-ijms-20-00372" ref-type="bibr">47</xref>,<xref rid="B140-ijms-20-00372" ref-type="bibr">140</xref>,<xref rid="B141-ijms-20-00372" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CaSki</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p53, Bax, caspase-3<break/>&#x02193; MEK-2, ERK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-ijms-20-00372" ref-type="bibr">141</xref>,<xref rid="B142-ijms-20-00372" ref-type="bibr">142</xref>] </td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colon</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HT29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p21, Bax<styled-content style="color:#424242">, </styled-content>caspase-9, caspase-3<break/>&#x02193; Bcl-2, NF-&#x003ba;B p65, &#x003b2;-catenin, cyclin D1, c-Myc, survivin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-ijms-20-00372" ref-type="bibr">42</xref>,<xref rid="B56-ijms-20-00372" ref-type="bibr">56</xref>,<xref rid="B143-ijms-20-00372" ref-type="bibr">143</xref>,<xref rid="B144-ijms-20-00372" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW620 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; Wnt-1, &#x003b2;-catenin, cyclin D1, c-Jun, MMP-7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B130-ijms-20-00372" ref-type="bibr">130</xref>,<xref rid="B131-ijms-20-00372" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCT116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p21<break/>&#x02193; cIAP-1, cIAP-2, survivin, cyclin D1, c-Myc, MMP-9, VEGF, ICAM-1, CXCR4, NF-&#x003ba;B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-ijms-20-00372" ref-type="bibr">59</xref>,<xref rid="B144-ijms-20-00372" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DLD-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p21, p27, caspase-7, caspase-9<break/>&#x02193; hTERT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-ijms-20-00372" ref-type="bibr">144</xref>,<xref rid="B145-ijms-20-00372" ref-type="bibr">145</xref>,<xref rid="B146-ijms-20-00372" ref-type="bibr">146</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Gastric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SGC-7901</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; Bax, caspase-3, caspase-9, cleaved PARP<break/>&#x02193; Bcl-2, c-Myc, p-ERK1/2, Raf-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B147-ijms-20-00372" ref-type="bibr">147</xref>,<xref rid="B148-ijms-20-00372" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNU-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; NF-&#x003ba;B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-ijms-20-00372" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNU-16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; cleaved PARP<break/>&#x02193; cyclin D1, Bcl-2, MMP-9, CXCR4, VEGF, NF-&#x003ba;B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-ijms-20-00372" ref-type="bibr">100</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ED40515</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-3, caspase-6, caspase-7, caspase-9, PARP, Bcl-2, Bcl-xL, XIAP<break/>&#x02193; FDFT1, NF-&#x003ba;B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-ijms-20-00372" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; cleaved Bid, cytochrome <italic>c</italic> release, caspase-8, caspase-9, caspase-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-ijms-20-00372" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NB-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; cleaved Bid, cytochrome <italic>c</italic> release, caspase-8, caspase-9, caspase-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-ijms-20-00372" ref-type="bibr">51</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-3, caspase-8, Bid, cytochrome <italic>c</italic>, Bax, cleaved PARP<break/>&#x02193; Notch-1, Hes-1, Bcl-2, NF-&#x003ba;B, uPA, survivin, Bcl-XL, MMP-9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-ijms-20-00372" ref-type="bibr">41</xref>,<xref rid="B134-ijms-20-00372" ref-type="bibr">134</xref>,<xref rid="B149-ijms-20-00372" ref-type="bibr">149</xref>,<xref rid="B150-ijms-20-00372" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H520</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; PARP, caspase-3<break/>&#x02193; Notch-1, Hes-1, Bcl-2, NF-&#x003ba;B, survivin, Bcl-XL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-ijms-20-00372" ref-type="bibr">96</xref>,<xref rid="B149-ijms-20-00372" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1299</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; Notch-1, Hes-1, uPA, MMP-9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B149-ijms-20-00372" ref-type="bibr">149</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIA PaCa-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; E-cadherin, EGR-1, Bax, p27Kip1<break/>&#x02193; NF-&#x003ba;B, Bcl-2, cIAP-1, survivin, cyclin D1, c-Myc, COX-2, VEGF, MMP-9, ICAM-1, CXCR4, N-cadherin, vimentin, p-MEK, p-AKT, p-GSK-&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-ijms-20-00372" ref-type="bibr">58</xref>,<xref rid="B98-ijms-20-00372" ref-type="bibr">98</xref>,<xref rid="B151-ijms-20-00372" ref-type="bibr">151</xref>,<xref rid="B152-ijms-20-00372" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L3.6pl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; E-cadherin<break/>&#x02193; N-cadherin, vimentin, VEGF, MMP-9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B151-ijms-20-00372" ref-type="bibr">151</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BXPC3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p27Kip1<break/>&#x02193; p-MEK, p-AKT, p-ERK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B152-ijms-20-00372" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW1990</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p27Kip1<break/>&#x02193; p-MEK, p-AKT, p-ERK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B152-ijms-20-00372" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANC-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B153-ijms-20-00372" ref-type="bibr">153</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreatic cancer stem cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; cleaved PARP<break/>&#x02193; Nanog, Sox-2, Oct-4, Notch-1, p-AKT, pERK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B151-ijms-20-00372" ref-type="bibr">151</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-9, cytochrome <italic>c,</italic> cleaved PARP, LC3-II<break/>&#x02193; p-Akt, &#x003b2;-catenin, Id-1, Bcl-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-ijms-20-00372" ref-type="bibr">19</xref>,<xref rid="B87-ijms-20-00372" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PC-3 (stem cell-like)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-3, cleaved PARP<break/>&#x02193; Id-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-ijms-20-00372" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNCaP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-9, caspase-8, caspase-7, caspase-3, cytochrome <italic>c</italic>, cleaved PARP, LC3-II<break/>&#x02193; Id-1, p-Akt</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-ijms-20-00372" ref-type="bibr">19</xref>,<xref rid="B87-ijms-20-00372" ref-type="bibr">87</xref>]</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Skin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G361</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; cleaved PARP, caspase-7, caspase-9, caspase-3, E-cadherin, &#x003b2;-catenin, &#x003b3;-catenin<break/>&#x02193; Snail, vimentin, &#x003b1;-SME, Twist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-ijms-20-00372" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; cleaved PARP, caspase-7, caspase-9, caspase-3, I&#x003ba;B, p-ATF2, p-c-Jun, p-SAPK/JNK<break/>&#x02193; PI3K p85, p-IKK&#x003b1;/&#x003b2;, I&#x003ba;B&#x003b1;/&#x003b2;, NF-&#x003ba;B p65, EGFR, Id-1, Id-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-ijms-20-00372" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A375 (stem cell-like)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; ABCG2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B155-ijms-20-00372" ref-type="bibr">155</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BLM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-3, caspase-4, cleaved PARP, Bax, BiP, PERK, p-eIF2&#x003b1;, IRE1&#x003b1;, ATF4, CHOP<break/>&#x02193; Bcl-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-ijms-20-00372" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A375</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; caspase-3, caspase-4, cleaved PARP, BiP, PERK, p-eIF2&#x003b1;, IRE1&#x003b1;, ATF4, CHOP, ERO1&#x003b1;<break/>&#x02193; Bcl-2, CDK4, Ras, caspase-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-ijms-20-00372" ref-type="bibr">48</xref>,<xref rid="B71-ijms-20-00372" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A2058</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193; CDK4, Ras, caspase-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-ijms-20-00372" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191; p-ERK<break/>&#x02193; Tyrosinase, MC1R, MITF, TYRP-1, TYRP-2, p-p38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-ijms-20-00372" ref-type="bibr">156</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Note: &#x02191;upregulation; &#x02193;downregulation; p&#x02014;, phosphorylated state. Abbreviations: ABCG2, ATP-binding cassette subfamily G member 2; Akt, or PKB, protein kinase B; ATF, activating transcription factor; ATP, adenosine triphosphate; Bcl-xL, B-cell lymphoma-extra large; BiP, or GRP78, glucose-regulated protein; CDK, cyclin-dependent kinase; CHOP, CCAAT-enhancer-binding protein homologous protein; cIAP, cellular inhibitor of apoptosis; COX-2, cyclooxygenase-2; CXCR4, C-X-C motif chemokine receptor 4; DR, death receptor; EGR, early growth response; eIF2-&#x003b1;, eukaryotic initiation factor 2 alpha; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; ERO1&#x003b1;, endoplasmic reticulum oxidation 1; ETK1, epithelial and endothelial tyrosine kinase; FDFT1, farnesyl-diphosphate farnesyltransferase 1; GSK-&#x003b2;, glycogen synthase kinase 3 beta; Hes-1, hairy and enhancer of split-1; hTERT, human telomerase reverse transcriptase; ICAM-1, intercellular adhesion molecules-1; Id-1, inhibitor of differentiation/DNA binding; I&#x003ba;B&#x003b1;/&#x003b2;, inhibitor of kappa B alpha/beta; IKK&#x003b1;/&#x003b2;, I&#x003ba;B kinase alpha/beta; IL-6, interleukin 6; IRE-1, inositol-requiring enzyme 1; JNK, c-Jun N-terminal kinase; LC3, microtubule-associated protein 1A/1B-light chain 3; MC1R, melanocortin 1 receptor; Mcl-1, myeloid cell leukemia 1; MEK, mitogen-activated protein kinase; MIC-1, macrophage inhibitory cytokine 1; MITF, melanogenesis associated transcription factor; MMP, matrix metalloproteinases; mTOR, mammalian target of rapamycin; NF-&#x003ba;B, nuclear factor kappa B; Oct-4, octamer-binding transcription factor 4; p27Kip1, cyclin-dependent kinase inhibitor 1B; PARP, poly(ADP-ribose) polymerase; PCNA, proliferating cell nuclear antigen; PERK, PKR-like ER-localized eIF2&#x003b1; kinase; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species; SAPK/JNK, stress-activated protein kinase/c-Jun NH2-terminal kinase; Sox-2, sex determining region Y-box 2; TGF-&#x003b2;1, transforming growth factor beta 1; TYRP, tyrosinase-related proteins; VEGF, vascular endothelial growth factor; uPA, urokinase-type plasminogen activator; Wnt, wingless/integrase; XBP, X-box binding protein; XIAP, X-linked inhibitor of apoptosis protein; &#x003b1;-SMA, alpha-smooth muscle actin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="ijms-20-00372-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-20-00372-t002_Table 2</object-id><label>Table 2</label><caption><p>Exemplar in vivo studies of tocotrienols for various cancer treatments using mouse models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tocotrienol(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Anticancer Effect(s)/Molecular Target(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRF or &#x003b4;-T3-enriched diet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b4;-T3-enriched diet decreased the number of colorectal tumors in an animal model, but not in TRF-fed group.</p></list-item><list-item><p>&#x003b4;-T3-enriched diet suppressed COX-2 protein levels in colorectal mucosa.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B157-ijms-20-00372" ref-type="bibr">157</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>TRF inhibited xenografts in mice by a regulation of Wnt pathways.</p></list-item><list-item><p>TRF increased expression of Wnt pathways related factors, i.e., Axin-2, GSK-3&#x003b2;, APC and decreased the protein expression of Wnt-1, &#x003b2;-catenin and &#x003b2;-catenin target genes, i.e., <italic>cyclin D1</italic>, <italic>c-Myc</italic> and <italic>survivin</italic> in the xenografts.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-ijms-20-00372" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b3;-T3 inhibited &#x0003e; 50% of tumor growth.</p></list-item><list-item><p>&#x003b3;-T3 downregulated microvessel density indicator CD31.</p></list-item><list-item><p>&#x003b3;-T3 downregulated NF-&#x003ba;B and NF-&#x003ba;B-regulated cyclin D1, COX-2, survivin, Bcl-xL, XIAP, ICAM-1, MMP-9 and VEGF.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-ijms-20-00372" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b3;-T3 inhibited cancer cell proliferation in tumor tissues.</p></list-item><list-item><p>&#x003b3;-T3 inhibited constitutive activation of NF-&#x003ba;B.</p></list-item><list-item><p>&#x003b3;-T3 significantly downregulated the expression of proinflammatory marker COX-2, suppressed the expression of invasion biomarker MMP-9, and inhibited the angiogenic biomarker VEGF in the tissues.</p></list-item><list-item><p>&#x003b3;-T3 reduced Bcl-2, cIAP-1, CXCR4, NF-&#x003ba;B, c-Myc.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-ijms-20-00372" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b4;-T3 inhibited pancreatic tumor growth and metastasis.</p></list-item><list-item><p>&#x003b4;-T3 inhibited epithelial-to-mesenchymal transition in pancreatic tumors as E-cadherin upregulated, N-cadherin, vimentin, VEGF, MMP-9, CD44 were downregulated.</p></list-item><list-item><p>&#x003b4;-T3 inhibited cancer cell proliferation and increased cleaved caspase-3.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B151-ijms-20-00372" ref-type="bibr">151</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b4;-T3 inhibited cancer cell proliferation, decreased phosphorylated MAPK expression and induced expression of p27Kip1.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B152-ijms-20-00372" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b4;-T3 significantly enhanced the survival of mice.</p></list-item><list-item><p>&#x003b4;-T3 decreased levels of p-AKT, p-MEK, p-ERK, NF-&#x003ba;B and Bcl-xL and increased levels of p27Kip1, Bax, CK18 and activated caspase-3.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B158-ijms-20-00372" ref-type="bibr">158</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b3;-T3 inhibited tumorigenicity of PC-3 cells in mice.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-ijms-20-00372" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;-T3 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b3;-T3 inhibited xenograft growth in nude mice.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-ijms-20-00372" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b3;-T3 inhibited the growth of xenograft.</p></list-item><list-item><p>&#x003b3;-T3 reduced PCNA, Ki-67 and Id1 in tumor tissues.</p></list-item><list-item><p>&#x003b3;-T3 increased cleaved PARP and cleaved caspase-3.</p></list-item><list-item><p>&#x003b3;-T3 increased expression levels for the tumor suppressor gene (<italic>E-cadherin</italic>) and its repressor (Snail).</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B159-ijms-20-00372" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b4;-T3 treatment disabled the formation of melanospheres completely in mice.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B155-ijms-20-00372" ref-type="bibr">155</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b4;-T3 inhibited the growth and progression of melanoma xenografts in nude mice.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-ijms-20-00372" ref-type="bibr">71</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="ijms-20-00372-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-20-00372-t003_Table 3</object-id><label>Table 3</label><caption><p>Recent clinical trials conducted using tocotrienols for various cancer treatments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Application(s) of Tocotrienols</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drugs Involved</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase: Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><uri>ClinicalTrials.gov</uri> Identifier</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" rowspan="1" colspan="1">Adjunct cancer treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">TRF and Tamoxifen</td><td align="center" valign="middle" rowspan="1" colspan="1">Pilot trial: Completed in 2010</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT01157026</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" rowspan="1" colspan="1">Health supplement</td><td align="center" valign="middle" rowspan="1" colspan="1">Gamma-Delta Tocotrienols and TRF</td><td align="center" valign="middle" rowspan="1" colspan="1">1: Completed in 2013</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT01571921</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" rowspan="1" colspan="1">Neoadjuvant treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Epirubicin, Cyclophosphamide, Docetaxel, Paclitaxel, Trastuzumab, Pertuzumab and Tocotrienols </td><td align="center" valign="middle" rowspan="1" colspan="1">2: Ongoing</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT02909751</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Colon</td><td align="center" valign="middle" rowspan="1" colspan="1">Adjunct cancer treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Irinotecan, Oxaliplatin, Calcium Folinate, 5-Fluorouracil and Tocotrienols</td><td align="center" valign="middle" rowspan="1" colspan="1">2: Ongoing</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT02705300</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" rowspan="1" colspan="1">Adjunct cancer treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Cisplatin, Vinorelbine, Carboplatin and Tocotrienols</td><td align="center" valign="middle" rowspan="1" colspan="1">3: Ongoing</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT02644252</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ovary</td><td align="center" valign="middle" rowspan="1" colspan="1">Adjunct cancer treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Bevacizumab and Tocotrienols</td><td align="center" valign="middle" rowspan="1" colspan="1">2: Ongoing</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT02399592</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ovary</td><td align="center" valign="middle" rowspan="1" colspan="1">Cancer treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">Cabazitaxel and/or Tocotrienols</td><td align="center" valign="middle" rowspan="1" colspan="1">2: Ongoing</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT02560337</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" rowspan="1" colspan="1">Cancer treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b4;-T3</td><td align="center" valign="middle" rowspan="1" colspan="1">1: Completed in 2016</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT00985777</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" rowspan="1" colspan="1">Health supplement</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b4;-T3</td><td align="center" valign="middle" rowspan="1" colspan="1">1: Completed in 2016</td><td align="center" valign="middle" rowspan="1" colspan="1">NCT01450046</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Health supplement</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;-T3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Completed in 2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01446952</td></tr></tbody></table><table-wrap-foot><fn><p>Note: Examples of clinical studies that are registered at <uri xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</uri> showing a status as accessed on 18th December 2018.</p></fn></table-wrap-foot></table-wrap></floats-group></article>